


Available online at [www.sciencedirect.com](http://www.sciencedirect.com)

ScienceDirect

[www.onlinepcd.com](http://www.onlinepcd.com)

## Special Article

# Cardiac Rehabilitation Delivery Model for Low-Resource Settings: An International Council of Cardiovascular Prevention and Rehabilitation Consensus Statement



Sherry L. Grace<sup>a,b,l,\*</sup>, Karam I. Turk-Adawi<sup>c</sup>, Aashish Contractor<sup>d,1</sup>, Alison Atrey<sup>e</sup>, Norman R.C. Campbell<sup>f</sup>, Wayne Derman<sup>g</sup>, Gabriela L.M. Ghisi<sup>a</sup>, Bidyut K. Sarkar<sup>h</sup>, Tee J. Yeo<sup>i</sup>, Francisco Lopez-Jimenez<sup>j</sup>, John Buckley<sup>k,1</sup>, Dayi Hu<sup>m</sup>, Nizal Sarrafzadegan<sup>n</sup>

<sup>a</sup>School of Kinesiology and Health Science, Bethune 368, York University, 4700 Keele Street, Toronto, Ontario, M3J 1P3, Canada

<sup>b</sup>Toronto Rehabilitation Institute, University Health Network, Toronto, Ontario, Canada

<sup>c</sup>School of Health Policy and Management, York University, 4700 Keele Street, Toronto, Ontario, M3J 1P3, Canada

<sup>d</sup>Rehabilitation and Sports Medicine, Sir H.N. Reliance Foundation Hospital, Raja Ram Mohan Roy Road, Mumbai, 400004, India

<sup>e</sup>Imperial College, 2 Bar Close, Stapleford, Cambridgeshire, CB22 5BY

<sup>f</sup>Libin Cardiovascular Institute of Alberta, University of Calgary, 3280 Hospital Drive NW, Calgary, Alberta, T2N 4Z6, Canada

<sup>g</sup>Institute of Sport & Exercise Medicine (SEM) within the Faculty of Medicine & Health Sciences at the University of Stellenbosch, Cape Town, South Africa

<sup>h</sup>Research Division, Public Health Foundation of India, ISID Campus, Vasant Kunj, New Delhi, India

<sup>i</sup>Department of Cardiology, National University Heart Centre, 5 Lower Kent Ridge Rd, Singapore 119074

<sup>j</sup>Cardiovascular Health Clinic and Cardiometabolic Program at Mayo Clinic, Rochester, MN, USA

<sup>k</sup>Institute of Medicine, University Centre Shrewsbury, UK

<sup>l</sup>International Council of Cardiovascular Prevention and Rehabilitation

<sup>m</sup>People Hospital of Peking University, 11# Xizhimen S. Ave, Beijing, 100044, China

<sup>n</sup>Isfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Khorram Ave, PO Box 81465-1148, Isfahan, Iran

## ARTICLE INFO

## Keywords:

Cardiac rehabilitation

Delivery models

Middle-income countries

## ABSTRACT

Cardiovascular disease (CVD) is a global epidemic, which is largely preventable. Cardiac rehabilitation (CR) is demonstrated to be efficacious and cost-effective for secondary prevention in high-income countries. Given its affordability, CR should be more broadly implemented in middle-income countries as well. Hence, the International Council of Cardiovascular Prevention

This is a collaborative work through the International Council of Cardiovascular Prevention and Rehabilitation (ICCP). Grant support: None.

Grant support: None.

Statement of Conflicts of Interest: see page 317.

Endorsed by: International Council of Cardiovascular Prevention and Rehabilitation, World Hypertension League, British Association of Cardiovascular Prevention and Rehabilitation, Singapore Heart Foundation, Grupo Interamericano de Prevención y Rehabilitación Cardiovascular, the Groupe Exercice Réadaptation Sport of the French Society of Cardiology, Group of Cardiopulmonary and Metabolic Rehabilitation of the Brazilian Society of Cardiology, the Russian National Society of Preventive Cardiology, the African Heart Network, Canadian Association of Cardiovascular Prevention and Rehabilitation, and the Australian Cardiovascular Health and Rehabilitation Association. A shorter version of this paper was previously published (Ref 12).

\* Address reprint requests to Sherry L. Grace, PhD, Professor, School of Kinesiology and Health Science, Bethune 368, York University, 4700 Keele Street, Toronto, Ontario, M3J 1P3, Canada.

E-mail address: [sgrace@yorku.ca](mailto:sgrace@yorku.ca) (S.L. Grace).

<http://dx.doi.org/10.1016/j.pcad.2016.08.004>

0033-0620/© 2016 Elsevier Inc. All rights reserved.

Community health  
Primary care

and Rehabilitation (ICCP) convened a writing panel to recommend strategies to deliver all core CR components in low-resource settings, namely: (1) initial assessment, (2) lifestyle risk factor management (i.e., diet, tobacco, mental health), (3) medical risk factor management (lipids, blood pressure), (4) education for self-management; (5) return to work; and (6) outcome evaluation. Approaches to delivering these components in alternative, arguably lower-cost settings, such as the home, community and primary care, are provided. Recommendations on delivering each of these components where the most-responsible CR provider is a non-physician, such as an allied healthcare professional or community health care worker, are also provided.

© 2016 Elsevier Inc. All rights reserved.

### Abbreviations and Acronyms

AHA = American Heart Association
BMI = Body mass index
BP = Blood pressure
CADE-Q = Coronary Artery Disease Education Questionnaire
CHD = Coronary heart disease
CR = Cardiac rehabilitation
CVD = Cardiovascular disease
DM = Diabetes mellitus
ECG = Electrocardiogram
HDL-C = High-density lipoprotein cholesterol
HF = Heart failure
HICs = High-income countries
HTN = Hypertension
ICCP = International Council of Cardiovascular Prevention and Rehabilitation
LDL-C = Low-density lipoprotein cholesterol
LICs = Low-income countries
LMICs = Low-income and middle-income countries
MI = Myocardial infarction:
MICs = Middle-income countries
PA = Physical activity
PSS = Psychosocial stress
PURE = Prospective Urban Rural Epidemiology study
QoL = Quality of life
SMS = Short message service
TGs = Triglycerides
WC = Waist circumference
WHO = World Health Organization

Cardiovascular disease (CVD) is global epidemic, but is at its worst in the developing world. Cardiac rehabilitation (CR) is an established model of care proven to reduce mortality and morbidity in patients with this disease.<sup>1–3</sup> While professional CR societies in high-income countries have published guidelines and recommendations on how to best deliver CR in the developed world,<sup>4–8</sup> there is scant guidance on how to practically and affordably deliver these programs in lower-resource settings such as middle-income countries (MICs).<sup>9</sup> Low-resource settings were defined according to the World Bank classification of low-income and middle-income countries (LMICs) based on gross national income.<sup>10</sup>

Given the last international-scale guidance on CR delivery in low-resource settings was almost 25 years ago from the World Health Organization,<sup>11</sup> the International Council of Cardiovascular Prevention and Rehabilitation (ICCP; [www.globalcardiacrehab.com](http://www.globalcardiacrehab.com)) endeavored to system-

atically develop practical, evidence-based recommendations on how to deliver each of the core components of CR, namely (1) initial assessment, (2) lifestyle risk factor management (i.e., physical activity (PA), diet, tobacco, and mental health), (3) medical risk factor management [e.g., lipid control, blood pressure (BP) control], (4) education for self-management; (5) return to work, and (6) outcome assessment.

The writing panel was comprised of CR practitioners and researchers from the MIC setting as possible, with expertise representing all the core components of CR. The methods for developing clinical practice recommendations, and the recommendations themselves, are published in a companion statement.<sup>12</sup> These were based on evidence from MICs where available, which was not often the case. We hope this consensus statement will incite more research in this area.

Adaptation of service provision by type of most-responsible healthcare provider is outlined subsequent to the model (Box 1). This is followed by recommendations and examples on how this model of CR can be delivered in more-accessible, less expensive settings, namely the community, home and primary care settings.

## Low-resource CR model

### Core components of CR

The core components of CR have been established by the major CR associations from high-income countries (HICs), namely the American,<sup>4</sup> Australian,<sup>5</sup> British,<sup>6</sup> Canadian,<sup>7</sup> and European associations.<sup>13</sup> These core components have also been agreed upon in the ICCP Charter, which has also been endorsed by CR associations in LMICs.<sup>14</sup> Herein each of the following common core components has been adapted for the MIC setting: 1) initial assessment, 2) lifestyle risk factor management (i.e., diet, tobacco, and mental health), 3) medical risk factor management (e.g., lipid control, BP control), 4) education for self-management; 5) return to work and 6) outcome evaluation. Strategies to implement the PA recommendations are found in the companion article.<sup>12</sup>

### Initial assessment

The CR program should commence with a comprehensive assessment. It is recommended that the style of the assessment be consistent with motivational interviewing.<sup>15</sup> Specifically, the assessment should be client-centered and goal-oriented. Each of the following elements should be considered in the intake

assessment: physical activity, diet, tobacco consumption, overweight/obesity, coronary heart disease (CHD) knowledge, depression, return to work, lipids, BP, medications and diabetes mellitus (DM).

**Physical activity.** It is strongly recommended that every patient, independent of the type of CR program in which she/he will engage, should have a pre-exercise assessment. The basic assessment should cover both past and current levels of PA (types and volume of all activities), physical examination, and aerobic exercise capacity. This assessment should ascertain if the patient has any of the recognized contraindications to exercise, determine the risk of a medical event during exercise, the best-suited exercise program for the patient, and inform development of an individualized exercise program and daily PA plan. In some instances, an exercise test of functional capacity may not be possible, for example if the patient is frail or has orthopedic limitations. However, even in low-resource settings an exercise evaluation is imperative (e.g., use of field-based tests of walking or step-up protocols).

A resting BP and digital pulse palpation or electrocardiogram (ECG) should be performed where possible to exclude tachycardia or bradycardia, and screen for other cardiac arrhythmias or adverse BP recordings that might contraindicate exercise. Due to the high prevalence of comorbidities, particularly musculoskeletal disorders in the population with chronic disease, exercise assessment should also include a musculoskeletal screen of all major joints.

Where possible, a test of functional capacity could be performed with every patient. It is preferable that each patient participating in CR undertakes a multi-stage exercise stress test. If a treadmill test is not possible, a cycle ergometer can be used (also useful if patients have musculoskeletal limitations that necessitate non-weight bearing exercise). If neither a cycle ergometer nor treadmill is available,<sup>16</sup> the 6-min walk test or a step test can be conducted.<sup>17</sup> Basic professional tools to conduct this pre-exercise assessment include: a sphygmomanometer, stethoscope, ECG machine/monitor (or at least an accurate exercise heart rate monitoring device where unavailable), beacons or markers for a 6-min walk test, and a stopwatch.

Recognized contraindications to exercise training include: unstable angina or acute myocardial infarction (MI), uncontrolled hypertension (HTN) (e.g., >180/110 mmHg, or >100 bpm), symptomatic orthostatic hypotension <20 mmHg, significant aortic stenosis, uncontrolled atrial or ventricular arrhythmias, sinus tachycardia >120 beats per minute, uncompensated heart failure (HF), third degree atrioventricular block, active endo/pericarditis or myocarditis, recent embolism, acute thrombophlebitis, acute systemic illness or fever, uncontrolled DM (glucose concentrations >16 mmol/l), severe orthopedic conditions that would prohibit exercise, and other metabolic conditions including acute thyroiditis, hypokalemia, and hyperkalemia. If testing for any of these is not available, clinical signs and symptoms of these entities should be determined.<sup>18</sup>

**Diet.** Assessment of dietary intake is complex.<sup>19</sup> Due to the number of variables associated with dietary intake (i.e., culture, translation validity, food availability) no one questionnaire

will be valid worldwide. Moreover, all dietary assessments in clinical practice are limited by the ability of the patient to recall intake accurately.

Food diaries with dietary analysis are often cited as the gold standard way of assessing dietary intake, but this is labor-intensive for both the patient and professional.<sup>20</sup> More objective measures (biomarkers, urine analysis, glucose monitoring) would not be practical in a MIC clinical setting. Food frequency questionnaires and checklists are more commonly used to reduce cost and time. One potential food frequency questionnaire stems from the Prospective Urban Rural Epidemiology (PURE) study.<sup>21,22</sup> More generic measures that can capture changes in dietary patterns and be interview-led by a trained professional would be most feasible in MICs. Any questionnaire should be validated prior to use.

There is a lack of studies that collect detailed information on dietary patterns in CR. CR programs could consider one of the following questionnaires, all of which have been used to score diet and relate it to CHD risk:

- The WHO STEPwise approach to chronic disease risk factor surveillance (STEPS) core diet items assessing fruit and vegetable consumption, and the expanded items related to fat consumption and eating foods not prepared at home.<sup>23</sup>
- The alternative healthy eating index.<sup>24</sup> It accounts for type of fat, forms of carbohydrate and sources of protein — elements which are highlighted in American Heart Association (AHA) guidelines.<sup>25</sup> It has been shown to be related to lower rates of chronic disease in both men and women.

The assessment should preferably include family members in the same household, especially the person who most often purchases food and beverages as well as prepares meals to ensure that it is as accurate as possible.

**Tobacco use.** Every individual should be asked if they currently use tobacco in any form. In some cultures, healthcare providers hesitate to ask women questions relating to tobacco consumption.<sup>26</sup> However, this must be done since there is a high degree of smokeless tobacco consumption among women in MICs.<sup>26,27</sup> If there is no current consumption of tobacco, assess for past consumption, if any. The WHO STEPS incorporates a core module to assess tobacco use, with an expanded section assessing quit attempts, use of smokeless tobacco and exposure to second-hand smoke.<sup>23</sup>

Among smokers, duration of smoking and degree of dependence should additionally be assessed. While motivational factors drive quit attempts, it is primarily cigarette dependence (such as daily consumption and time to first cigarette of the day) that predicts successful quitting.<sup>28,29</sup> The Fagerstrom Test for Nicotine Dependence and Heavy Smoking Index are the most standardized and validated tools used for the purpose of assessing nicotine dependence, and should be incorporated into all CR programs.<sup>30,31</sup>

**Overweight/obesity.** Overweight/obesity should be assessed via two measures: body mass index (BMI) and waist circumference. Using the formula weight/(height × height), BMI is obtained,

## Box 1

**Algorithm for CR Delivery Based on Availability of Healthcare Personnel.**

There is a paucity of trained healthcare personnel to deliver CR in low-resources settings, particularly with expertise across all core components. It is recommended that MICs establishing or augmenting CR services establish a competent body to provide requisite training on all aspects of CR, to non-physicians as well as general practitioners. We recommend that academic institutions offering advanced cardiac services appoint clinical educators tasked with training CR providers at non-academic and developing CR centers, and that policies are enacted so that local laws and health care practice allow non-physicians to deliver CR. In future versions of this statement, we hope to establish training standards for CR professionals delivering care in low-resource settings.

**SCENARIO ONE**

Informally-trained community health worker

**ASSESSMENT**

- Verbally assess family and personal history of heart attack, angina, stroke, transient ischemic attack and diabetes
- Verbally assess physical activity history, including occupational or transportation activity. Also query for any musculoskeletal pain with exercise.
- Verbally assess functional capacity and any contraindications to exercise (patients should not be prescribed exercise in the presence of contraindications as outlined in the assessment section); identify activities patient perceives as light to moderate-intensity (not breathing too hard)
- Verbally assess consumption of foods high in saturated and trans fat, salt and sugar and alcohol (e.g., probe intake of processed, street and restaurant foods), as well as fruit and vegetable intake. Preferably use items from WHO STEPs if available in local language.
- Verbally assess self-reported tobacco consumption.
- Take weight (in kilograms) using weighing scale, waist circumference (in centimeters) using measuring tape, and height (in meters) using wall-mounted measuring tape. Calculate body mass index (BMI) using the formula  $\text{weight}/(\text{height in m})^2$
- Verbally assess occupation type, employment status, and desired occupational status
- Verbally assess whether they have been told by a healthcare provider that they have raised BP or cholesterol. If yes to either, ask whether they are taking any treatments
- Use WHO-Five Well-Being Index for depression screening, if diagnostic and treatment services are available
- Take BP reading using validated, automated, BP measuring instrument.
- Assess for raised blood glucose or diabetes, using urine test strips or glucometer, if available
- Document in a paper-and-pencil chart, stored confidentially

**LIFESTYLE MANAGEMENT**

- Regular lifestyle physical activity should be recommended to all patients.  
In addition, for low-risk patients, light to moderate-intensity exercise should be prescribed on at least 3, but preferably most days of the week. Intensity to be monitored via subjective assessment of rating of exertion and symptoms. Non-equipment based exercises like walking would be the most feasible option. Location of exercise: community setting or the patient's home.  
For patients at medium and high-risk of an acute adverse event during exercise or with contraindications, only supervised physical activity is recommended (scenario 2 or 3).
- Overall dietary recommendations should be aligned to a cardio-protective dietary pattern with large intake of plant-based foods (vegetables, fruits, pulses, legumes, whole grains, nuts, seeds), allow unsaturated fat intake, low intake of saturated and trans fat (less processed and refined food), encourage intake of fish and poultry instead of red meat, if culturally-acceptable, locally available and affordable
- If tobacco user, provide detailed quit advice using ask, advise, assess, assist and arrange (5As) protocol and information about quitting support options.
- If face-to-face contact is not feasible for follow-up at community level due to resource constraints or distance, consider alternate methods of delivery of tobacco cessation, physical activity and dietary advice messages by using mobile technology like SMS and pre-recorded voice messages
- If BMI > 25 (kg/m<sup>2</sup>) or waist circumference exceeds WHO/IDF thresholds for abdominal obesity (based on region-specific cut-offs), advise patient on risks of obesity and recommend target BMI/waist circumference
- Educate patients (and their family if possible) based on their information needs (e.g., risk factors, medications and side effects, monitoring cardiac symptoms, and dealing with cardiac emergencies), and promote health behavior change
- Stress management: in addition to physical activity, offer deep breathing, progressive muscle relaxation, guided imagery, yoga, and/or meditation
- If urine test positive for glucose, refer to formally-trained healthcare worker/physician if available  
If fasting blood sugar >100 mg/dl, offer dietary advice and physical activity counseling for impaired fasting glucose.  
If fasting blood sugar >126 mg/dl, on two or more occasions, refer to formally-trained healthcare worker/physician if available



**MEDICAL MANAGEMENT**

- If patient is taking acetylsalicylic acid (ASA), reinforce continued use. If not, prescribe ASA, if available and patient does not have a contraindication (i.e., gastrointestinal disorder or bleeding, blood disorders)
- For patients without regular access to a formally-trained healthcare provider to support comprehensive secondary prevention, assess risk factors at regular intervals through follow-up visits (e.g., monthly contact) for 6 months to ensure effective monitoring of health status, and timely referral to formally-trained healthcare provider where warranted.
- Consider assessing compliance to medication, as applicable. If patient is non-adherent, enquire regarding reasons for this and reiterate importance of adherence; If patients have a valid clinical reason for non-adherence (e.g., muscle aches), inform treating physician accordingly. If patient is adherent, provide encouragement and positive feedback.
- Document treatment plan and provide a copy to primary care provider, where available

**EQUIPMENT NEEDED:**

BP measuring device and Stethoscope  
 Measuring tape (loose, as well as wall-mounted)  
 Weigh scale  
 Urine test strips  
 Glucometer, with strips, batteries  
 Stopwatch  
 Beacons or markers for 6-minute walk test  
 Home-made weights for resistance training  
 Paper and pencil; secure and confidential filing

**SCENARIO TWO**

Trained healthcare worker

Same as scenario one, but additionally:

**ASSESSMENT**

- Six-minute walk test to assess safety for exercise training, to develop exercise prescription, and consider return to work. Observe for chest pain, and appropriate heart rate response with exertion.
- If patient aims to return to work, review region-specific requirements and/or vocational restrictions for return to work following a coronary event. This may include considerations in completion of disability forms. Undertake occupational assessment to ascertain safety to return to same vocation, or whether to recommend alternative employment (provide contacts for employment agencies).
- If lab facility available and if affordable, send blood sample for lipid profile

**LIFESTYLE MANAGEMENT**

- Patient at moderate risk for adverse event during activity can be supervised during physical activity in this setting
- Dietary advice should be individualized to a patient's risk factor profile, including weight management for obesity.
- If tobacco user, provide option of Nicotine Replacement Therapy where available

**MEDICAL MANAGEMENT**

- If depressed, initiate cognitive behavioral therapy where trained providers available
- Discuss how patients are tolerating cardiac medications and any side-effects.

**ADDITIONAL EQUIPMENT RECOMMENDED:**

Resistance bands  
 Hand weights  
 Gym and yoga mats  
 Pedometers  
 Sphygmomanometer (regularly calibrated manual device to back up automated device)  
 Watch to measure heart rate  
 Automated external defibrillator

**SCENARIO THREE**

Trained physician (or licensed independent practitioners that can clinically supervise and prescribe CR)

Same as scenario two, but add:

**ASSESSMENT**

- Digital palpation of pulse and reading of baseline ECG to rule out any arrhythmia. Pulse oximeter reading for assessment of level of oxygen saturation.
- Exercise stress test (treadmill or cycle with ECG) to develop individualized exercise prescription and to assess readiness / safety of return to work (as applicable). Advise patient on exercise prescription and recommended time for return to work.
- Send blood sample for fasting blood sugar (if diabetic) and lipid profile.
- Other tests, such as renal (for diuretics) and liver (for statins) profiles should be done as required on a per-case basis.

**LIFESTYLE MANAGEMENT**

If tobacco user, consider pharmacotherapy such as Varenicline or bupropion. (Varenicline may be unaffordable in LMIC settings)

**MEDICAL MANAGEMENT**

- If depression unremitted, prescribe generic selective serotonin reuptake inhibitor.
  - For BP above 140 mm Hg systolic or 90 mm Hg diastolic, treat with an ACE inhibitor. Diuretics may be added if BP requires additional lowering.
  - Initiate (or reinforce if already prescribed) low-dose statins for all patients, unless contraindicated.
  - In the presence of hypertension and dyslipidemia, prescribing the polypill may be warranted to promote adherence, if available
  - If patient has heart failure: educate patient on self-management strategies to avoid acute decompensation
  - For type 1 diabetes, treat with insulin. For type 2 diabetes: if overweight, advise weight reduction and if needed metformin. For type 2 diabetes with normal weight, start with sulphonylurea.
  - For blood sugar above 126 mg/dl, test urine for albumin. If no albuminuria, start with low-dose diuretics. If albuminuria present, then start with low-dose diuretics and ACE inhibitor.
- Regular follow-up.
- Refer to credible, public, government-owned health facility if affordability of medication is an issue.

**ADDITIONAL EQUIPMENT:**

Pulse oximeter to assess PO<sub>2</sub> saturation and pulse rate

Exercise equipment (e.g. treadmill and/or stationary bicycle)

Electrocardiogram machine

Tertiary care centre with cardiopulmonary assessment capability

Access to laboratory with blood and urine analysis capability

where height is measured in meters and weight is measured in kilograms. For BMI, values 25 to 29.9 kg/m<sup>2</sup> and above denote an overweight state and values 30 kg/m<sup>2</sup> and above denote obesity,<sup>32</sup> however these thresholds do vary by region and ethnicity. In Asians for instance, the WHO has suggested BMI thresholds of 23 to 27.5 kg/m<sup>2</sup> and  $\geq 27.5$  kg/m<sup>2</sup> to denote increased risk and high risk for CHD, respectively.<sup>33</sup> BMI status should be communicated to all patients.

Waist circumference (WC) is measured in accordance with the WHO recommendations at the midpoint between the lower margin of the least palpable rib and the top of the iliac crest, using a stretch-resistant measuring tape.<sup>34</sup> This should be done in the standing position with feet together and arms at the side in a relaxed stance at end-expiration. Excess clothing should be removed prior to application of the measuring tape. The average of 2 measurements should be calculated and used as the final value. Cut-offs for central obesity measured by WC also vary by region and ethnicity.<sup>35</sup> Region-specific limits for WC should also be made known to all patients (see Table 6 of Alberti et al. 2006).<sup>35</sup> Again, height, weight and WC are incorporated in WHO STEPs.<sup>23</sup>

**CVD knowledge.** CR providers should have a comprehensive understanding of their patients' health literacy and health information needs to inform development and implementation of educational programs.<sup>36–40</sup> The assessment of these needs supports tailoring the information delivered in CR. The Information Needs in CR scale,<sup>41</sup> is a useful tool, assessing the heart (i.e., physiology, symptoms and their management, conditions), nutrition, exercise/PA, medication, work/social roles, psychosocial stress (PSS), emergency/safety, diagnosis and treatments, as well as risk factors.

**Mental health.** Several clinical practice guidelines for CVD care and CR recommend that all patients with CHD be screened for depression.<sup>7,42,43</sup> It is also recommended that patients be screened for PSS. Whether screening is of benefit in the context

of CR is unknown.<sup>44</sup> No studies have addressed the potential harms of screening, such as false-positive results, the cost and inconvenience of additional follow-up assessments, the adverse effects or costs associated with treating incorrectly-diagnosed patients, and inappropriate labeling. Thus, herein it is cautiously and initially recommended that CR programs screen patients, unless the program has no access to healthcare professionals to undertake formal diagnostic interviews or to evidence-based treatments.<sup>43</sup>

The WHO-Five Well-Being Index can be used,<sup>45</sup> and is available in many languages.<sup>46</sup> Alternatively, the AHA guidelines recommend screening with the two-item Patient Health Questionnaire (PHQ-2).<sup>43</sup> Patients who screen positive should be administered the PHQ-9. Stress can be assessed with the 2-item tool developed for the INTERHEART study.<sup>47</sup>

**Return to work.** Following a CHD event, CR providers should elicit desired occupational status from patients. Patients needing to return to paid work should be asked to describe the degree of force exerted on their job to facilitate risk assessment (i.e., whether their occupation is sedentary, or involves light to very heavy work). Again, the WHO STEPs measure includes core questions on work-related PA that could be used for this purpose.<sup>23</sup>

Timing of return to work should be discussed, taking into consideration the family's economic situation, the degree of force used on the job, and whether the nature of work could be modified. Information on type of CHD and acute treatment received should be obtained to guide decision-making. Resumption of other unpaid roles should also be considered, including the degree of force required for these activities. Similarly, resumption timing and modification options should be discussed for safety.

**Lipids.** Undertaking a blood draw for lipid assessment depends on the availability of equipment for venipuncture as well as laboratory support for processing of blood samples. Where

available, components of the lipid profile that should be obtained are: total cholesterol, triglycerides (TGs) and high-density lipoprotein cholesterol (HDL-C). Low-density lipoprotein cholesterol (LDL-C) is calculated using the Friedewald equation:  $LDL-C = Total\ Cholesterol - HDL-C - TGs \times 0.20$  (if units mg/dL and 0.45 if units mmol/L).<sup>48</sup> The Friedewald equation is known to underestimate LDL-C levels when TGs levels are elevated.<sup>49</sup> Nonetheless, direct measurements of LDL-C have been found to correlate well with LDL-C estimated by the Friedewald equation.<sup>50</sup> Fasting is not essential as non-fasting levels have been shown to correlate well with CHD risk.<sup>51</sup> Total cholesterol assessment is included in core module of WHO STEPs, with TGs and HDL-C included in the expanded module.<sup>23</sup>

Regular assessment of lipid levels enables monitoring of therapeutic targets following commencement of lipid-lowering therapy, where available. This is crucial for individuals with established CHD as they are at high risk for future adverse CVD events and should receive lipid-lowering therapy regardless of baseline LDL-C levels.

**Blood pressure.** BP assessment should include both the seated (for usual therapeutic and diagnostic decision-making) and standing positions (for postural hypotension). BP assessment should utilize an automated device (semi-automated or fully-automated or a device designed to assess BP without an observer present) that has passed international standards for accuracy and that uses an upper-arm cuff.<sup>52,53</sup> In general, devices designed for self-measurement are not robust enough for clinical use. The website <http://www.dablededucational.org/> can be used to select BP devices that have passed international accuracy standards. People with high readings (i.e., greater than or equal to 140/90 mmHg) at two or more visits and those on treatment for HTN with BP readings less than 140/90 mmHg are considered to have HTN.<sup>54</sup>

**Cardio-protective medication use.** Medications may not be available and affordable in the MIC setting. Where available, patient use of, adherence to, tolerance of, and contraindication for cardio-protective therapies should be assessed and documented at the intake assessment. These may include anti-platelets, angiotensin-converting enzyme inhibitors (as well as angiotensin receptor blockers), beta-blockers, statins and other anti-HTN medications.

**Diabetes mellitus.** Patients should be asked whether they have a history of DM. There are several core items in the WHO STEPs to ascertain history, and if positive, forms of treatment. Fasting blood glucose should be assessed where available.<sup>23</sup>

At the completion of the comprehensive formal assessment, documentation should be made of the findings. The client and the CR provider should discuss a plan of treatment accordingly. The CR program should then include the following elements, as applicable to each patient:

#### *Lifestyle risk factor management*

Strategies to implement the physical activity core component recommendations are found in the companion version of this consensus statement.<sup>12</sup>

**Diet.** Unhealthy eating patterns are a significant contributor to CHD mortality, and influence many risk factors associated with CHD.<sup>55,56</sup> The consumption of foods high in saturated and industrially-produced trans-fat, salt, sugar and alcohol contributes to a high percentage of deaths from non-communicable diseases.<sup>57</sup>

Dietary patterns in MICs have dramatically changed over the last two decades due to globalization, the free movement of goods, services, technology, food processing, distribution and marketing. This has resulted in a more 'Westernized' diet.<sup>19,58</sup> An example of this is the increase in consumption of animal products and sugar-sweetened beverages observed in China, resulting in increased caloric intake, the glycemic load of diets and obesity levels.<sup>59–61</sup> Some eastern MIC dietary patterns have also changed from a high plant and grain-based diet to a diet higher in meat, dairy and eggs.<sup>62</sup> The PURE study showed that a healthy diet was followed by just under half the population of patients with CHD or a stroke in all the countries included (high through low), while the figure was less than one-quarter of the population in low-income countries.<sup>63</sup> In wealthier countries, red meats and fried foods were more commonly consumed, whereas in poorer countries, foods such as fruits and vegetables may be cost-prohibitive.<sup>63</sup>

Diet therapy is an integral part of the secondary prevention and treatment of CHD. While there are examples of nutritional interventions (group and individual) in CHD patients in the literature, these are mainly from HICs.<sup>64,65</sup> Evidence in MICs is very limited.

#### *Dietary recommendations*

Due to the large difference between MICs, approaches to improving the quality of diet will differ. Possible challenges may include variation in cooking methods, cultural and religious influences, tastes, availability, and affordability of foods.

The Mediterranean is an example of a dietary pattern has been shown to reduce CHD mortality and morbidity.<sup>66</sup> The components of this diet work together to improve CHD risk factor control. It is comprised of a wide variety and large intake of plant-based foods; fruit, vegetables, legumes, pulses, whole grains, nuts and seeds. It is also relatively high in fat intake; but mostly unsaturated fats (MUFA and PUFA) and low in saturated fat and trans-fatty acids. Poultry and fish are eaten rather than red meat, and there is a low intake of processed and refined foods.<sup>67</sup>

Helping people change their dietary habits will involve changing their lifestyle behaviors, which can be extremely difficult due to barriers to both implementation and maintenance. Unsurprisingly, patients do not respond uniformly to dietary interventions, so identification of underlying factors that may affect their readiness or motivation to change is necessary. Interventions in MICs should be sufficiently adapted to the cultural context and involve community members – both in the intervention design and in implementation – for the intervention to work.<sup>68</sup>

#### *Type of healthcare provider delivering dietary intervention*

Dietitians use their training in promotion of behavioral change as well as their nutritional knowledge to help patients improve their diet. Access to dietitians varies considerably within and

across different countries.<sup>9</sup> Consequently, it is important to identify alternative methods to deliver dietary messages. For example, many CR interventions in HICs provide group dietary education sessions led by a dietitian, but there are some studies that have shown that interventions delivered by other specifically trained health professionals also can promote improved dietary habits.<sup>64</sup> For example, community leader-led diet interventions have been shown to be successful in other disease populations.<sup>69</sup>

### Tobacco

MICs are at the mid-stage of the tobacco epidemic, and have not yet witnessed the full brunt of the premature mortality due to smoking and smokeless tobacco use.<sup>70,71</sup> Hence, there is limited amount of research on tobacco cessation interventions for delivery at the individual-level conducted in MICs.<sup>72</sup> Guidelines formulation for tobacco cessation support for CR in MICs thus needs to build on the existing evidence of efficacy for smoking cessation interventions from HICs, supplemented by the limited but valuable research from MICs. This entails assessing the generalizability of findings from HICs about the efficacy of the existing smoking cessation interventions by placing them within MIC settings and considering the contextual issues of affordability, availability, accessibility, cultural acceptability and feasible delivery mechanisms. Further, for MIC countries in Asia like India and Bangladesh, where smokeless tobacco users outnumber smokers, efficacious and appropriate interventions for smokeless tobacco cessation are critical.<sup>26,27</sup>

The evidence for the major interventions available to promote and aid tobacco cessation that can be delivered in the CR setting is reviewed in Table 1. By far the largest body of evidence is on cessation of smoking rather than smokeless tobacco. The interventions consist of psychological and pharmacological approaches, with the former being more feasible in lower-resource settings.

**Table 1 – Efficacy of smoking cessation interventions.**

Intervention (Reference)	Efficacy
Advice from physician <sup>73</sup>	OR 1.66 (95% CIs 1.4 to 1.9)
Brief advice (< 20 min & up to 1 follow up)	OR 1.84 (95% CI 1.6 to 2.1)
Intensive intervention (>20 min and multiple follow-ups or other additions)	
Individual face-to-face counseling <sup>74</sup>	OR 1.6 (95% CI 1.3 to 1.8)
Telephone counseling <sup>75</sup>	OR 1.3–1.4 (95% CI 1.2 to 1.5)
Nursing interventions <sup>76</sup>	OR 1.5 (95% CI 1.3 to 1.7)
Tailored self-help interventions <sup>77</sup>	OR 1.2 (95% CI 1.0 to 1.4)
Group behavioral support <sup>78</sup>	OR 2.0 (95% CI 1.6 to 2.5)
Training health professionals <sup>79</sup>	OR 1.7 (95% CI 1.5 to 2.0)
Mobile phones <sup>80</sup>	OR 1.8 (95% CI 1.6 to 2.0)
Nicotine replacement therapy (NRT) <sup>81</sup>	OR 1.6 (95% CI 1.5 to 1.7)
NRT gum	OR 1.5 (95% CI 1.4 to 1.6)
NRT patch	OR 1.6 (95% CI 1.4 to 1.9)
Nicotine lozenge/tablets	OR 1.9 (95% CI 1.4 to 2.7)
Bupropion <sup>82</sup>	OR 1.56 (95% CI 1.10 to 2.21)
Varenicline <sup>82</sup>	OR 2.96 (95% CI 2.12 to 4.12)
Low-dose varenicline <sup>79</sup>	OR 3.98 (95% CI 2.01 to 7.87)
Cytisine <sup>83</sup>	OR 1.82 (95% CI 1.66 to 2.0)
Behavioral support plus pharmacotherapy <sup>84</sup>	OR 1.60 (95% CI 1.26 to 2.03)

Behavioral support involves one or more sessions of advice and discussion aimed at increasing the success of quit attempts. It can be delivered one-to-one, in pairs or in groups. It usually involves multiple sessions lasting between 15 min to an hour each delivered by trained personnel (non-physician). The WHO recommends using five steps, also called the five 'A's, as a protocol for counseling on smoking cessation.<sup>85</sup> These are: Asking about tobacco use at every visit; Advising those who consume tobacco to quit in a clear, strong and personalized manner; Assessing their readiness to quit; Assisting in their quit attempt and Arranging for appropriate follow-up and reinforcement.

The feeling of reward experienced by smokers and the inability to stop in spite of wanting to quit are due to the nicotine present in cigarette smoke which is an addictive substance. It has now been proven that nicotine from cigarette smoke gets rapidly absorbed into the bloodstream and binds with alpha 4 beta 2 receptor acetylcholine-nicotinic receptors in the ventral tegmental area of the brain.<sup>86</sup> Nicotine replacement therapy aims to make it easier to stop smoking by providing nicotine to reduce the craving and withdrawal symptoms and to occupy nicotinic receptors, such that if a lapse occurs the cigarette is less rewarding. Multiple delivery options are available, namely gum, transdermal patches, inhalers, lozenges, sublingual tablets, as well as nasal and mouth spray. Nicotine replacement therapy is a pharmacological intervention, but in most countries it is available over-the-counter. However, in some countries prescription is required for the higher-dose products.

## Pharmacological interventions: where physicians and medications, are both available and affordable

### Bupropion

Bupropion is an atypical antidepressant approved to be prescribed to aid smoking cessation by reducing nicotine cravings and withdrawal symptoms. It has been shown to double the chances of remaining abstinent for a year.<sup>82,87,88</sup> It requires prescription by a physician and is not very expensive. It is available in several MICs.

### Varenicline

Varenicline is a recently-approved agent for tobacco cessation.<sup>89</sup> It is a nicotinic partial agonist that targets the alpha 4 beta 2 receptor. It reduces craving and nicotine withdrawal symptoms and reduces the rewarding effects of smoking. It is much more effective than Bupropion. It requires a physician's prescription and is quite expensive, and therefore may not be a feasible recommendation to patients.

### Cytisine

Cytisine is a partial agonist targeting the alpha 4 beta 2 nicotinic receptor, and is the drug on which varenicline was modeled.<sup>83,90</sup> It is obtained from laburnum seeds and has been prescribed for smoking cessation in eastern European



countries like Poland and Russia for many years. It is not licensed in most countries, but would be affordable for MICs if licensed.

### Smokeless tobacco cessation interventions

Evidence on the effectiveness of methods of smokeless tobacco cessation is still an area of emerging research, but some guidelines have been formulated.<sup>91</sup> Authors of the only Cochrane review on smokeless tobacco cessation in 2011 concluded that while there is evidence of clinically-significant benefit of behavioral interventions (11 out of 14 trials reported benefit, including seven which reported statistically significant benefit), bupropion (OR [odds ratio] = 0.9; CIs [confidence intervals] 0.5–1.6) and nicotine replacement therapy (OR = 1.14; CIs 0.9–1.4) have not shown significant benefit for smokeless tobacco users.<sup>92</sup> A single trial of varenicline published since the review has shown benefit (OR = 1.6; CIs 1.1–2.4). On the other hand, a recently-published trial in 2013 conducted in India of the effect of varenicline on smokeless tobacco use did not find a significant benefit.<sup>89</sup> In summary, the limited evidence currently available on efficacy of interventions for stopping smokeless tobacco has not shown clear evidence for efficacy of medications, but there is evidence for behavioral support.<sup>84,92</sup>

### Overweight/obesity

In patients with established CHD, the prevalence of overweight and obesity far exceeds that in the general population.<sup>93</sup> Large international epidemiological studies including those in MICs reveal up to 78% of CHD patients are overweight and up to 53% are obese.<sup>56,94</sup> Overweight and obesity are associated with various adverse CVD outcomes, including increased risk of angina,<sup>95</sup> CVD death and MI.<sup>56,96</sup> In MICs, the population attributable risk for abdominal obesity ranges from 29.3% to 48.5%, with increases in BMI accounting for up to 9% of deaths from CHD.<sup>97</sup>

The implementation of public awareness programs in MICs to highlight the significant burden of overweight and obesity has been highlighted as one of the most cost-effective approaches for primary and secondary prevention. Furthermore, the WHO and World Obesity Federation have emphasized the promotion of healthy diet and PA as a crucial strategy in tackling the global epidemic of overweight and obesity.<sup>98</sup> Indeed, weight loss via increased PA and dietary modification is the mainstay of managing obesity.<sup>99</sup> Benefits of weight loss are dose-dependent, and sustained weight loss of 5%–10% of baseline weight within 6 months has been shown to improve CVD risk factor control.<sup>99</sup> (See recommendations 1 and 2 for PA and healthy diet, respectively, in the companion article).<sup>12</sup>

Pharmacotherapy for treatment of obesity is not recommended in MICs due to limited options, difficulty sustaining weight loss and lack of cost-effectiveness.<sup>100</sup> Similarly, bariatric surgery as a therapeutic option is not considered herein due to lack of infrastructure for tertiary surgical units in MICs.

### Mental health

Depression, anxiety, stress from work, relationships and finances, social isolation, as well as anger and hostility among cardiac patients may complicate or hamper recovery.<sup>101</sup> Due to the lack of formally-trained psychotherapists in most low-resource settings, a practical method to address PSS in CR is through mental health education and PSS management (i.e., relaxation techniques, coping strategies). Patients also often report that the social support they receive from peers and providers in the CR setting facilitates coping with their heart condition and promotes their psychosocial well-being.

Depression is considered an emerging risk factor for CHD.<sup>102</sup> Slowed thinking, decreased pleasure, decreased purposeful PA, guilt and hopelessness as well as disordered eating and sleeping may be seen in the depressive syndrome.<sup>103</sup> In HICs, it is reported that about 20% of CVD patients have major depression,<sup>104</sup> with many more reporting elevated depressive symptoms. Depression is a leading cause of disability in MICs,<sup>105</sup> and given the burden of CHD in these countries, it is expected that the rate of comorbidity would be even higher.

Comorbid depression is related to greater mortality and morbidity when compared to patients with CHD alone.<sup>106</sup> It is predicted that the CVD event rate in CHD patients with severe depression is double over one year. Moreover, depression is associated with increased drop-out from CR.<sup>107</sup> Given this high burden and negative impact of depression on patient's quality of life (QoL), CR guidelines from HICs recommend screening and treatment for depression. Effective treatment options for depression include cognitive behavioral therapy and anti-depressant medications. In HICs, selective serotonin reuptake inhibitors are shown to be safe in CVD patients, and to result in moderate reductions in depressive symptoms.<sup>108</sup>

There has been a trend towards harm with PSS intervention provided to women with CHD by non-psychologically trained personnel.<sup>109</sup> Moreover, there is a paucity of research on the treatment of comorbid depression in MICs. Therefore it is recommended at this time that formal treatment not be initiated where trained providers are not available. This is because PA as part of CR is shown to reduce depressive symptoms to a similar magnitude as psychotherapy and anti-depressants.<sup>110</sup>

### Medical risk factor management

#### Lipid control

Based on international large-scale studies incorporating patients from MICs, the prevalence of elevated total cholesterol levels (widely accepted as >200 mg/dL or 5.2 mmol/L) in those with established CHD ranges from 40% to as high as 77%.<sup>19</sup> Cholesterol is a major culprit in CVD risk and outcomes in MICs. Raised cholesterol accounted for more than 70% of additional CHD deaths over time,<sup>111,112</sup> and abnormal lipids carry a population attributable risk of almost 50%.<sup>56</sup>

Management strategies for cholesterol lowering include lifestyle modifications, namely dietary changes and PA (See recommendations 1 and 2 for PA and healthy diet, respectively, in the companion article),<sup>12</sup> as well as pharmacotherapy. Of the variety of available lipid-lowering drugs, treatment of elevated cholesterol with statins remains the cornerstone of secondary prevention of CHD. Robust evidence extrapolated from HICs has demonstrated that LDL-C reduction corresponds to lowering of CHD risk regardless of baseline LDL-C levels.<sup>113</sup> Several international guidelines, including those recently-published by the International Atherosclerosis Society, have recommended lowering of LDL-C to less than 70 mg/dL (or 1.8 mmol/L) as an optimal therapeutic target for patients with established CHD as part of secondary prevention.<sup>114,115</sup> All patients with CHD should be prescribed statin therapy for LDL-C lowering regardless of baseline lipid levels unless contraindicated, regardless of baseline lipid levels, even when resources and affordability do not permit cholesterol measurement. Choice of statin will depend on cost-effectiveness studies performed for individual countries/regions.

However, studies investigating statin use in MICs reveal dismal prescription and compliance rates, ranging from 1.4 to 29.8%.<sup>19,116</sup> Lower socioeconomic status is associated with worse compliance. The CR team should promote medication adherence.<sup>117</sup> The polypill presents a potential solution for improving compliance rates,<sup>118</sup> where access is not an issue.

The program physician, designated healthcare professional, or primary care provider should be consulted when cardio-protective medication adjustment is needed, to ensure that patients achieve the recommended targets for BP and lipids (and blood glucose, as applicable).

### Blood pressure control

Increased BP is a leading risk for death and disability globally.<sup>119</sup> Hypertension is present in the majority of people with CHD, and is causal in about half of CHD and HF cases, where increased BP has a particularly ominous course.<sup>120</sup>

Lifestyle changes and medications are effective in reducing high BP (Information on exercise and diet is provided in the companion article).<sup>12</sup> With regard to the latter, anti-HTN drug therapy (see Recommendations 9 and 10 in the companion article)<sup>12</sup> can substantially lower the risk of recurrent CVD events; sequential addition of anti-HTN medications to achieve BP targets (i.e., <140/90 mmHg) is recommended in people with HTN who also have CHD and HF.<sup>121</sup>

### Cardio-protective medications

Medications like aspirin, ACE-inhibitors and beta-blockers have been demonstrated to reduce CVD events and mortality in patients with CHD, regardless of the presence of HTN or other specific risk factors. Cardio-protective medications recommendations, where available and affordable, are shown in the companion article (See recommendations 10).<sup>12</sup> Finally, management of diabetes within the CR context was considered beyond the scope of the current recommendations. Readers are referred elsewhere.<sup>122</sup>

## Education to promote self-management for heart-health behavior changes

As outlined above, for persons with CHD, behavior changes (i.e., PA, improved diet, medication adherence and smoking cessation) are highly effective in reducing risk. These behavior changes required are multi-factorial, necessitating patient understanding and long-term adherence to optimize health outcomes.<sup>7,123</sup> Indeed, meta-analyses have demonstrated the importance of patient education for improving self-management behaviors<sup>124</sup> and health-related QoL, and potentially reducing healthcare costs and recurrence of acute CVD events.<sup>125</sup>

A recent systematic review has demonstrated the benefits of educational interventions in CHD, through increasing patients' knowledge and behavior change.<sup>123</sup> Of the 42 included studies, one was undertaken in the MIC Turkey.<sup>126</sup> Results of this small quasi-experimental study with nurse-delivered education demonstrated improvements in risk factors (i.e., BP, lipids, BMI, smoking), as well as diet and exercise, but not medication adherence.

### Developing and delivering patient education in CR

CR education materials and content should be consistent with patient's level of health literacy and cultural beliefs. Health literacy may be lower in MIC settings where there is less exposure to health information and healthcare providers. Testing the health literacy of patients enables healthcare providers to: (1) match the readability level of materials to the reading skills of patients, (2) know whether supplemental teaching is needed, and (3) know when it is necessary to introduce different types of educational materials (e.g., audio-visuals, demonstrations).<sup>127</sup> CR programs should offer instruction at a level which is understandable to patients.<sup>127</sup>

It is suggested that the educational intervention be delivered with a basis in behavior change theory. Theories such as the Health Action Process Approach model,<sup>128</sup> social cognitive theory,<sup>129</sup> and adult learning principles are particularly applicable for CR education.<sup>130</sup> An example of social cognitive theory use is the self-management model, which has been shown to be effective in CVD patients.<sup>131</sup> In this model CR participants learn to monitor their health behavior and the circumstances under which it occurs, including identifying proximal goals to motivate themselves and to enlist social supports to sustain their efforts.<sup>132</sup>

CR sessions are delivered over several weeks or months permitting repeated patient contact with healthcare providers, enabling fulsome education regarding the numerous lifestyle changes and treatments shown to reduce risk over time.<sup>133</sup> Among the content areas on which cardiac patients should be educated are: the heart (i.e., physiology, diagnoses), nutrition, exercise/PA, medication, work/vocational/social role resumption, PSS, safety in relation to cardiac symptoms and emergencies, tests and treatments, and risk factors.<sup>41</sup> Information provided should match patients information needs, and be delivered in a format which is congruent with patient preferences (e.g., written materials, group and individual education sessions, multimedia).

## Return to work

In MICs, return to paid roles following a CHD event bears significant individual and societal importance for economic reasons. Occupational assessment is recommended for patients wanting to resume employment where available, with particular emphasis on physically-demanding occupations and jobs involving public safety (e.g., vocational driving). Risks related to the nature of the patient's job in relation to their health status should be weighed. Exercise testing is warranted in selected patients to assess functional capacity, myocardial ischemia and/or electrical instability. Patients who are able to carry out >7 metabolic equivalents of work without angina, with left ventricular ejection fraction of >40% by echocardiography (where available), and with no electrocardiographic changes suggestive of ischemia or electrical instability on exercise stress testing (where available) can be considered low-risk individuals. These patients may return to work as early as 2 weeks after the treated CHD event.<sup>134</sup> Identification of these individuals at low-risk of adverse CVD events facilitates cost-effective early return to work.<sup>135</sup> These general criteria can be adapted and modified to existing guidelines for return to work.<sup>136</sup>

Psychosocial (e.g., mood, job satisfaction, motivation) rather than clinical (e.g., cardiorespiratory fitness) factors have been found to play an important role in individual's return to paid work in HICs.<sup>137</sup> Whether these factors are central in MICs is not known. Because acute mental and physical stressors can induce myocardial ischemia, both the physical and psychological demands of the patient's work should be considered. Efforts should be made to identify these issues, and promote work modifications for the patient, including negotiation of gradual return to work, where feasible. For patients who cannot safely return to their jobs, CR providers could provide them with the contact information for employment agencies.

Patients who return to work, particularly those who return within 2 weeks of their CHD event, should nevertheless receive comprehensive CR. Alternative delivery models should be applied, such as home-based CR (see Section home-based CR below).

## Outcome assessment tools

Re-assessment, as well as audit and evaluation, is considered a core component of CR.<sup>138</sup> The goal is to test whether patients are meeting treatment targets at program completion and have made significant changes through their participation. Where possible, an electronic database should be used to support ease of evaluation. To rule out potential biases, also where feasible, programs should attempt to assess all consecutive patients pre and post-program. Where patients' drop out, they should be called back for re-assessment where possible.

Given that many recommendations for CR delivery herein are based on evidence stemming from high-income countries or consensus, the writing panel particularly encourages evaluation wherever these recommendations are applied. Indeed the ICCPR plans to undertake field and feasibility tests of this model in future, using the assessment tools outlined below to inform future iterations of this consensus statement. Where formal

evaluation (not simply quality auditing) is undertaken for research purposes, protocols should be approved by a local institutional research ethics board, and all patients should provide written, informed consent. If feasible, incorporation of a control or comparison group, and randomization of participants to the consensus model versus a comparison group should be built into the evaluation design. It is hoped that in future all recommendations will be evidence-based.

## Functional capacity

A half to 1 MET increase in functional capacity from pre to post-program is an important marker of CR outcome, particularly because an increase of this magnitude is associated with significantly lower morbidity and mortality.<sup>139</sup> As outlined above, the gold standard assessment is an exercise stress test, where available. The six-minute walk test can also be used to measure progress with respect to changes in functional capacity as the program continues.

## Lifestyle risk factors

### Physical activity

A low-cost, exercise adherence and monitoring tool is a pedometer.<sup>140</sup> While walking for 1.6 km equates to 2000 steps on average, and walking for 30 min a day would on average register 3000 to 4000 steps, patients should aim to gradually increase step counts (at intensities which are asymptomatic) to reach 5400 to 7000 or more steps per day.<sup>140</sup> Walking 6500 steps/day is considered consistent with the clinical guideline recommendations to accrue 150 min of physical activity per week. If a pedometer is not available, the WHO STEPs includes core items assessing recreational activity and active forms of transportation,<sup>23</sup> or patients can be asked to record their activity in a log.

### Nutrition

It is essential that patients' dietary habits are re-assessed at the end of the program. The same tool should be administered at each assessment point, so that change in dietary patterns can be measured. See the recommended tools in the initial assessment Section Diet, which are sensitive to change.

### Tobacco abstinence

At each CR visit, tobacco consumption must be assessed in current and former smokers. One of the drawbacks of self-reported assessment is the possibility of socially-desirable reporting. There are several objective methods which can be used to assess tobacco consumption. These include assessment of carbon monoxide in exhaled air by a portable monitor. This gives immediate results and verifies whether the person has smoked in the past 24 h. Carbon monoxide is one of the constituents of cigarette or Bidi smoke, and the level should be below 10 ppm.

### Overweight/obesity

Re-assessment of BMI and WC is indicated in all patients at program completion. Patients should be informed of changes observed, and whether they have met thresholds outlined in the initial assessment Section *Overweight/obesity*.

### Education/knowledge

The Coronary Artery Disease Education Questionnaire (CADE-Q) assesses patients' knowledge about CHD, and was validated in CR patients in the MIC Brazil.<sup>141</sup> The CADE-Q failed to assess all core components of CR, such as nutrition and psychosocial risk. Therefore, the CADE-Q II was developed and psychometrically-validated.<sup>142</sup> It has been demonstrated to be sensitive to change from pre to post-CR and as such should be administered at both points, but has not yet been validated in LMICs.

### Depression

To assess change in depressive symptoms from pre to post-program it is recommended that again the WHO-Five Well-Being Index,<sup>143</sup> or the PHQ-9<sup>43</sup> be administered in accordance with AHA guidance.<sup>43</sup> Preferably the same scale should be administered at both assessment points. The PHQ-2 is a screener only, and would not be sufficient to detect changes in depressive symptoms, so programs may wish to consider administering the PHQ-9 pre-program as well.

### Return to work

Post-CR, patients should be asked whether their occupational status (as assessed via WHO STEPS; see the initial assessment Section Return to work) is consistent with their desired status. Time in days from CHD event to return to work should be recorded. Where applicable, patients should be asked whether their CHD symptoms were well-managed upon return to work, and to rate their satisfaction with their support in return to work by the CR program.

### Medical risk factors

#### Lipids

Resource availability permitting, all patients with established CHD should have assessment of lipid levels pre and post-program. Moreover, upon initiating pharmacotherapy, reassessment of lipid levels should be performed every 6 to 8 weeks when dose adjustment is necessary, and every 4 to 6 months once treatment targets have been achieved.<sup>115</sup> Outcome assessment can be performed by monitoring medication adherence (see iii below) and proportion of patients achieving target values of LDL-C. The WHO STEPS Instrument contains two questions (H14 and H19) that specifically assess if individuals are taking oral therapy for raised cholesterol, and if statins are consumed.<sup>23</sup>

#### Blood pressure

BP values should be measured as outlined in the assessment section, and the degree of change from pre to post-program considered. In general, values should be less than 140/90 mmHg at program exit.<sup>121</sup> Programs should aim for hypertension control to be achieved in the majority of patients (>70%) and for a minimum 20% improvement in control if the initial control rates are less than 50%.<sup>144</sup>

### Cardiac medication adherence

Patient use of, adherence to, tolerance of, and contraindication for cardio-protective therapies should be re-assessed and documented at the discharge assessment. Adherence to medications

could be assessed with the 8-item Morisky Medication Adherence Scale, or pill counts/prescription refills.<sup>145</sup>

### Program utilization

Rates of referral and enrolment should be captured, and potentially wait times. Patients' adherence to the program and completion should be described, and reasons for dropout, be they clinical or otherwise, recorded. Other indicators of the structure, process and outcomes of CR, including data definitions have been developed in high-income settings.<sup>146,147</sup>

Finally, where possible, ascertainment of long-term healthcare utilization, as well as morbidity and mortality would be ideal.

---

## Adaptation of the CR model by type of most-responsible healthcare provider

Herein a comprehensive model for CR delivery in low-resource settings has been initially proposed. Similar to the "Secondary Prevention for All in Need" model previously forwarded,<sup>148</sup> the model is conceived as menu-based and flexible to be applicable in a variety of lower-income contexts and regions of the globe. Depending on the health system structure of each country, and the availability of trained healthcare providers, general practitioners or family physicians, nurses or other allied healthcare providers as well as community health workers can be engaged to deliver CR.<sup>149</sup> Box 1 displays approaches to risk factor assessment as well as lifestyle and medical management where the most highly-trained profession represented in a CR program is: (1) a community healthcare worker, or (2) an allied healthcare provider or nurse.

---

## Adaptation of CR for LMICS

There is now ample evidence that CR is equivalently-effective in high-income countries whether it is delivered in a formal facility or through a home-based model.<sup>150,151</sup> Clearly, delivery of CR without requirement for a facility and the associated costs would be much more feasible in low-resource settings. The section below considers key ways CR could be adapted to be more feasibly delivered in low-resource settings, through community, the home, the internet/mobile technology and within primary care. Box 2 provides a case example of CR delivery in a low-resource setting.

### Community-based CR

Most notably for LMICs, community-based CR has emerged as an alternative modality to traditional hospital-based CR.<sup>152</sup> For the purpose of this consensus statement, community-based CR refers to delivery of all the core components of traditional CR, but where patients engage in their prescribed exercise in a non-medical setting, such as a community center for example. A recent systematic review showed that community-based programs in high-income countries are as effective as hospital-based programs in lowering CHD risk factors and re-hospitalization as well as improving physical function.<sup>152</sup> A more recent study



## Box 2

**Case Example: Cardiac Rehabilitation in Iran.**

The first Cardiac Rehabilitation (CR) program in Iran was established in 1996 at the Isfahan Cardiovascular Research Centre, after which several other programs were established. To optimize their program, the CR staff have attended short-term courses in other countries to learn about best practices and alternative delivery models.

Their CR program consists of 20 sessions delivered over approximately 2 months. Their program is comprehensive, including risk factor assessment and control, structured exercise, patient education (including for patients' families and members of the community at high risk of cardiovascular disease) and psychosocial counseling. They also offer a home-based program.

The last 10 sessions are free if patients consent to use their information for research purposes. Their lab data, exercise test results, and echocardiographic findings are documented and then used for research purposes. After completion of the CR program, patients are followed up every three months by telephone to ascertain mortality, as well as re-hospitalization and its causes, including revascularization procedures.

The main barrier to patient participation was financial. The leadership lobbied the Ministry of Health and private insurance companies to achieve CR reimbursement. Based on evidence of the benefits of, and provision of CR in high-income countries, including economic, in 2000 the Ministry sent a directive to hospitals with cardiac services to offer CR and insurance companies now reimburse. As a result, an increase in CR participation has been observed.

This CR center also offers professional development courses for healthcare providers to promote establishment of more CR programs in Iran and neighboring countries. These cover the goals of CR, the roles of members of the multi-disciplinary CR team, management of patients with different risk factors and referral indications, and protocols for the management of cardiac emergencies.

demonstrated that a community-based CR program had similar effects as a hospital-based program on health-related QoL, PSS, exercise frequency, and smoking rates.<sup>153</sup>

The WHO promotes delivery of rehabilitative services including CR for chronic disease management in the community, especially in low-resource-settings.<sup>11</sup> This may enable affordable and sustainable CR services by making use of a community's available resources such as buildings and human resources. Community-based CR in LMICs could be delivered by trained healthcare personnel or community health workers (see algorithm in Box 1).

For example, a successful community-based project supported by the WHO was undertaken in Indonesia between 2003 and 2006, which aimed to reduce chronic disease risk factors. Non-communicable disease risk factor services were integrated in a public health center that provided basic health services, including anthropometry measurement, BP measurement, promotion of a healthy diet, exercise, and smoking cessation.<sup>154</sup>

Moreover, in Indonesia, while there is a lack of hospital-based CR programs, there are more than 2500 Healthy Heart Clubs around the country. These clubs are affiliated with the Indonesian Heart Foundation, and provide community-based exercise programs for healthy persons and patients with CVD.<sup>155</sup> Unfortunately however, there is no single published article on the components, staff, or effectiveness of these community-based clubs. As another example, in India, availability of structured, supervised CR programs is similarly limited; however, there are several community-based, free-standing centers which are not affiliated with hospitals that offer secondary prevention services for CVD patients.<sup>156</sup>

A more comprehensive community-based CR model is delivered in Singapore.<sup>157</sup> The Singapore Heart Foundation Heart Wellness Centers offers a wide range of services, equipment and multidisciplinary healthcare expertise for primary and secondary prevention of CHD. Physiotherapists assess heart patients during the initial session to evaluate their physical abilities, medical limitations and health conditions. Patients are then prescribed individualized exercise programs, and they attend scheduled sessions. A variety of exercise equipment is available including treadmills, stationary bicycles, arm cycles, rowers, steppers, cross-trainers, and resistance training machines or dumbbells. Other services provided are nutritional counseling, smoking cessation counseling, health education sessions, and social support from other heart patients in the program. The program is run by physiotherapists, nutritionists, and smoking cessation counselors. The health talks are delivered twice a month by multidisciplinary healthcare professionals including cardiologists and cardiothoracic surgeons.<sup>158</sup> Recently, the effectiveness of this community-based CR program was evaluated. The results showed reduction in CHD risk factors (i.e., body fat and lipids), as well as improvement in exercise tolerance with patients' able to walk a significantly longer distance after 12 months than their baseline. A randomized controlled trial to evaluate the model is currently underway, to include 1000 patients over five years.<sup>158</sup>

**Home-based CR**

Home-based CR delivery can range from simple (i.e., paper-based educational material) to technologically-advanced (i.e., internet-based). Home-based CR has been successfully implemented in LMICs.<sup>159,160</sup> For example, in India, the Dream Program is a comprehensive, unsupervised CR program.<sup>159</sup> At hospital discharge, patients attended a briefing session and were given educational materials regarding the CR components including exercise, diet, and stress management for home practice. To track the progress of patients, they were asked to complete, on a daily basis, a self-evaluation chart consisting of all the components of CR. In addition, frequent follow-up (every 15th day) was offered through visits to the hospital-based CR unit. Upon re-assessment at the end of the 3 month program, this program was shown to be effective in reducing CVD risk factors including resting rate pressure, fasting blood sugar, total cholesterol, TGs and anthropometric indices as well as improving functional capacity.<sup>159</sup>

Another study of home-based CR was reported in Brazil.<sup>161</sup> The model was comprised of 3 months of unsupervised

exercise classes with bi-weekly telephone monitoring by a physician. Before starting the program, patients attended two supervised classes in a gymnasium led by a physiotherapist and received education on exercise and CHD risk factors. The home-based PA included stretching exercises and walking for 30 min, three times per week on non-consecutive days. A pre-post evaluation of this program demonstrated improvement in aerobic capacity and QoL, despite its low cost, and with an adherence rate of 100%.<sup>161</sup>

In China, a 6-week home-based CR program was delivered through a program manual provided to patients before hospital discharge.<sup>162</sup> Patients had a 1-h session where each section was introduced, and relaxation skills (i.e., tai chi) were demonstrated. The manual contained 3 sections: (1) 6 weekly topics on health education such as anatomy and physiology of the heart, signs and symptoms of MI, stress management, a home exercise plan, and relaxation; (2) answers to commonly-asked questions about medication, cardiac procedures, and anxiety and depression after MI; and (3) information on risk factors.<sup>162</sup> Compared to a usual CR group, the home-based participants had significantly higher scores on QoL and significantly lower anxiety.

Other home-based CR program models delivered in high-income countries are somewhat hybrid.<sup>163,164</sup> This approach would be particularly promising in LMICs, particularly incorporating mobile devices,<sup>165</sup> as programs could make use of publically-available resources.

### Mobile technology

With 5 billion mobile phone users around the world, there is an increasing trend to use mobile technology in healthcare delivery.<sup>166</sup> According to the International Telecommunication Union, the mobile penetration rate is 90.2% in LMICs, which is 78% of the global subscriptions.<sup>167</sup> Clearly, mobile delivery represents an accessible approach for CR. Moreover, CR delivery via a mobile has the potential to overcome resource challenges in LMICs, such as cost, infrastructure, and human resource constraints.<sup>163</sup>

Mobile delivery methods in LMICs include voice calls, text messaging, and voicemail messages sent to the user's voicemail inbox with short message service (SMS) notification.<sup>166</sup> SMS messages can be personalized and motivate behavioral change. Other delivery methods observed in high-income countries include smartphone applications with electrocardiogram and heart rate monitoring. The mobile applications applied in the CR setting include step-counting, visual feedback, text message reminders, educational videos, web portals, and diaries for recording weight, BP, and PA.<sup>163</sup>

Mobile technology has been used successfully in low-resource settings for non-CR health care delivery, such as the integrated community case management model for infectious diseases delivered by community health workers in African countries, including in remote areas.<sup>166</sup> In those settings, mobile has been used for education and raising awareness regarding required behavior changes, as well as for monitoring patients' health condition and promoting adherence to medication regimens.<sup>166</sup> Although no evaluation of the impact of these interventions on health outcomes in LMICs is available currently, a randomized controlled trial in sub-Saharan Africa showed

that text messaging via mobile phones resulted in increased medication adherence.<sup>168</sup>

Because mobile technology is a recent and growing health delivery modality, there is need for research to establish its effectiveness (even in high-income countries). A recent review provides initial evidence for the feasibility and acceptability of using mobile technology for CR.<sup>163</sup> For example, some studies showed that mobile-based delivery of CR is effective in improving self-efficacy, physical activity, exercise capacity, and general, physical, and mental health scores in patients with CHD.<sup>163,169</sup> More recently, the first randomized controlled trial on smartphone, a mobile with advanced features including applications, use for CR delivery revealed compelling results of significant improvement in CR utilization as well as improving functional capacity and psychological health outcomes as hospital-based program.<sup>164</sup>

Although there are no published data from LMICs on CR delivery via mobile, a randomized controlled trial is underway in Jordan (a middle-income country).<sup>165</sup> The aim of the study is to examine effect of a 6-month behavioral change intervention delivered via mobile on PA. The intervention consists of individualized consultation calls and motivational reminder text messages delivered once a week for 3 months, then bi-weekly for another 3 months.<sup>165</sup> Though results have not yet been published, the principal investigator indicates results are promising (E. AlSaleh, March 12, 2014: personal contact).

### Integration of CR within the primary health care system

In high-resource settings, CR is most-commonly delivered in the hospital setting with program oversight by a specialist physician. Given that specialty care is less available than primary care in LMICs, if broad reach to the many patients with CHD is to be achieved, CR may better be developed in the primary care setting. Indeed, the WHO has the goal to ensure universal access to primary health care. As the integration of preventive and management services for HTN and DM and some other non-communicable disease in the primary healthcare setting has been successful,<sup>170,171</sup> the same approach may be warranted to achieve broader implementation of CR in LMICs.

---

## Conclusion

These are the first recommendations by a global body in almost 25 years on how CR can be delivered practically in the MIC setting. While each core component is addressed separately herein, it is conceived that the lifestyle and behavior elements weave consistently across all the recommendations, and should be applied in a patient-centered manner.

There are large variations in the levels of healthcare resources available in low-resource settings; the recommendations should be implemented as possible. Moreover, there is a paucity of trained healthcare personnel to deliver CR in low-resources settings, particularly with expertise across all these core components. It is recommended that MICs establishing or augmenting CR services establish a competent body to provide requisite training on all aspects of CR, to non-physicians as well as general practitioners. We recommend that academic

institutions offering advanced cardiac services appoint clinical educators tasked with training CR providers at non-academic and developing CR centers. In future updates of this statement, we hope to establish training standards for CR professionals delivering care in low-resource settings.

### Statement of conflicts of interest

None of the authors have any conflicts of interests with regard to this publication.

### Acknowledgments

We gratefully thank the following Advisory Panel members for their thorough review of the manuscript: Ana Mola, PhD, Director of Care Transitions and Population Health Management, NYU Medical Langone Medical Center; Lis Neubeck, PhD, Senior Lecturer, Sydney Nursing School, Charles Perkins Centre, University of Sydney; Nana Pogossova, MD, Professor of Cardiology, Head of the Federal Health Center and Department of Non-communicable Diseases Prevention, National Research Center for Preventive Medicine/Russia; Rod Taylor, PhD, Professor and Chair of Health Services Research, University of Exeter Medical School, Veysey Building, Salmon Pool Lane, Exeter, UK; Rajesh Vedanthan, MD MPH, Assistant Professor, Zena and Michael A. Wiener Cardiovascular Institute, Department of Medicine, Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, USA. We gratefully thank Maureen Pakosh, MIST for undertaking the literature search supporting this statement.

### REFERENCES

- Anderson L, Oldridge N, Thompson DR, Zwisler AD, Rees K, Martin N, et al. Exercise-based cardiac rehabilitation for coronary heart disease: Cochrane systematic review and meta-analysis. *J Am Coll Cardiol*. 2016;67:1-12.
- Menezes A, Lavie C, Milani R, Forman D, King M, Williams M. Cardiac rehabilitation in the United States. *Prog Cardiovasc Dis*. 2014;56:522-529.
- Menezes A, Lavie C, Forman D, Arena R, Milani RV, Franklin BA. Cardiac rehabilitation in the elderly. *Prog Cardiovasc Dis*. 2014;57:152-159.
- AACVPR. *Guidelines for Cardiac Rehabilitation and Secondary Prevention Programs*. ed. 5. Champaign, Illinois: Human Kinetics. 2013.
- Woodruffe S, Neubeck L, Clark RA, Gray K, Ferry C, Finan J, et al. Australian Cardiovascular Health and Rehabilitation Association (ACRA) core components of cardiovascular disease secondary prevention and cardiac rehabilitation 2014. *Heart Lung Circ*. 2015;24:430-441.
- The British Association for Cardiovascular Prevention and Rehabilitation. The BACPR standards and core components for cardiovascular disease prevention and rehabilitation. [http://www.bacpr.com/resources/46C\\_BACPR\\_Standards\\_and\\_Core\\_Components\\_2012.pdf](http://www.bacpr.com/resources/46C_BACPR_Standards_and_Core_Components_2012.pdf); 2012. [accessed 13 Feb 2015].
- Stone JA, Arthur HM, Suskin N. *Canadian Guidelines for Cardiac Rehabilitation and Cardiovascular Disease Prevention: Translating Knowledge into Action*. ed. 3. Winnipeg, MB: Canadian Association of Cardiac Rehabilitation. 2009.
- Piepoli MF, Corra U, Adamopoulos S, Benzer W, Bjarnason-Wehrens B, Cupples M, et al. Secondary prevention in the clinical management of patients with cardiovascular diseases. Core components, standards and outcome measures for referral and delivery: a policy statement from the Cardiac Rehabilitation Section of the European Association for Cardiovascular Prevention & Rehabilitation. Endorsed by the Committee for Practice Guidelines of the European Society of Cardiology. *Eur J Prev Cardiol*. 2014;21:664-681.
- Cortes-Bergoderi M, Lopez-Jimenez F, Herdy AH, Zeballos C, Anchique C, Santibañez C, et al. Availability and characteristics of cardiovascular rehabilitation programs in South America. *J Cardiopulm Rehabil Prev*. 2013;33:33-41.
- The World Bank. Countries and Lending Groups. <http://data.worldbank.org/about/country-classifications>. [accessed 12 May 2014].
- World Health Organization. *Rehabilitation After Cardiovascular Diseases, with Special Emphasis on Developing Countries: Report of a WHO Committee*. Geneva: WHO. 1993.
- Grace SL, Turk-Adawi K, Contractor A, Atrey A, Campbell N, Derman W, et al. Cardiac rehabilitation delivery model for low-resource settings. *Heart*. 2016, <http://dx.doi.org/10.1136/heartjnl-2015-309209>. [heartjnl-2015-309209].
- Piepoli MF, Corra U, Adamopoulos S, Benzer W, Bjarnason-Wehrens B, Cupples M, et al. Secondary prevention in the clinical management of patients with cardiovascular diseases. Core components, standards and outcome measures for referral and delivery. *Eur J Prev Cardiol*. 2012;0:1-18.
- Grace SL, Warburton DR, Stone JA, Sanderson BK, Oldridge N, Jones J, et al. International charter on cardiovascular prevention and rehabilitation: a call for action. *J Cardiopulm Rehabil Prev*. 2013;33:128-131.
- Hancock K, Davidson PM, Daly J, Webber D, Chang E. An exploration of the usefulness of motivational interviewing in facilitating secondary prevention gains in cardiac rehabilitation. *J Cardiopulm Rehabil Prev*. 2005;25:200-206.
- Borghi-Silva A, Mendes RG, Trimer R, Cipriano Jr G. Current trends in reducing cardiovascular disease risk factors from around the world: focus on cardiac rehabilitation in Brazil. *Prog Cardiovasc Dis*. 2014;56:536-542.
- ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. *Am J Respir Crit Care Med*. 2002;166:111-117.
- Fletcher GF, Ades PA, Kligfield P, Arena R, Balady GJ, Bittner VA, et al. Exercise standards for testing and training: a scientific statement from the American Heart Association. *Circulation*. 2013;128:873-934.
- Mendis S, Abegunde D, Yusuf S, Ebrahim S, Shaper G, Ghannem H, et al. WHO study on prevention of recurrences of myocardial infarction and stroke (WHO-PREMISE). *Bull World Health Organ*. 2005;83:820-829.
- Ferruzzi M, Coulston AM, Boushey CJ. *Nutrition in the Prevention and Treatment of Disease* (ed 3). Waltham, MA: Academic Press. 2012.
- Bharathi AV, Kurpad AV, Thomas T, Yusuf S, Saraswathi G, Vaz M. Development of food frequency questionnaires and a nutrient database for the prospective urban and rural epidemiological (PURE) pilot study in South India: methodological issues. *Asia Pac J Clin Nutr*. 2008;17:178-185.
- Dehghan M, Iliw R, Zatonska K, Szuba A, Zhang X, Mente A, et al. Development, reproducibility and validity of the food frequency questionnaire in the Poland arm of the Prospective Urban and Rural Epidemiological (PURE) study. *J Hum Nutr Diet*. 2012;25:225-232.



23. World Health Organization. WHO STEPS Instrument (Core and Expanded): the WHO STEPwise Approach to Noncommunicable Disease Risk Factor Surveillance (STEPS). Geneva: WHO. 2000.
24. McCullough ML, Feskanich D, Stampfer MJ, Giovannucci EL, Rimm EB, Hu FB, et al. Diet quality and major chronic disease risk in men and women: moving toward improved dietary guidance. *Am J Clin Nutr.* 2002;76:1261-1271.
25. Lichtenstein AH, Appel LJ, Brands M, Carnethon M, Daniels S, Franch HA, et al. Diet and lifestyle recommendations revision 2006: a scientific statement from the American Heart Association nutrition committee. *Circulation.* 2006;114:82-96.
26. Indian Institute of Population Sciences (IIPS). *Global Adult Tobacco Survey India 2009–2010.* New Delhi: Ministry of Health and Family Welfare, Government of India. 2010.
27. World Health Organization. Global Adult Tobacco Survey: Bangladesh. Fact Sheet, Summary Report, Bangladesh. [http://www.who.int/tobacco/surveillance/global\\_adult\\_tobacco\\_survey\\_bangladesh\\_report\\_2009.pdf](http://www.who.int/tobacco/surveillance/global_adult_tobacco_survey_bangladesh_report_2009.pdf) 2009. [accessed 15 Oct 2015].
28. Kotz D, West R. Explaining the social gradient in smoking cessation: it's not in the trying, but in the succeeding. *Tob Control.* 2009;18:43-46.
29. Vangeli E, Stapleton J, Smit E, Borland R, West R. Predictors of attempts to stop smoking and their success in adult general population samples: a systematic review. *Addiction.* 2011;106:2110-2121.
30. Heatherton T, Kozlowski LT, Fagerström KO. The Fagerström test for nicotine dependence: a revision of the Fagerström tolerance questionnaire. *Br J Addict.* 1991;86:1119-1127.
31. Fagerström K. Time to first cigarette; the best single indicator of tobacco dependence? *Monaldi Arch Chest Dis.* 2003;59:91-94.
32. World Health Organization. *Obesity and Overweight: Fact Sheet No. 311.* Geneva: WHO. 2014.
33. World Health Organization. Appropriate body-mass index for asian populations and its implications for policy and intervention strategies. *Lancet.* 2004;363:157-163.
34. World Health Organization. *Waist Circumference and Waist-Hip Ratio: Report of a WHO Expert Consultation.* Geneva: WHO. 2011.
35. Alberti KGM, Zimmet P, Shaw J. Metabolic syndrome a new world-wide definition. A consensus statement from the international diabetes federation. *Diabet Med.* 2006;23:469-480.
36. French KS. Transforming nursing care through health literacy ACTS. *Nurs Clin North Am.* 2015;50:87-98.
37. Nouri SS, Rudd RE. Health literacy in the "oral exchange": an important element of patient-provider communication. *Patient Educ Couns.* 2015;98:565-571.
38. Cranton P. *Planning Instruction for Adult Learners.* Toronto: Wall and Emerson. 1989.
39. Scott J, Thompson D. Assessing the information needs of post-myocardial infarction patients: a systematic review. *Patient Educ Couns.* 2003;50:167-177.
40. Timmins F, Kaliszzer M. Information needs of myocardial infarction patients. *Eur J Cardiovasc Nurs.* 2003;2:57-65.
41. Ghisi GL, Santos RZ, Bonin CB, Roussenoq S, Grace SL, Oh P, et al. Validation of a Portuguese version of the Information Needs in Cardiac Rehabilitation (INCR) scale in Brazil. *Heart Lung.* 2014;43:192-197.
42. Herridge ML, Stimler CE, Southard DR, King ML, AACVPR Task Force. Depression screening in cardiac rehabilitation: AACVPR task force report. *J Cardiopulm Rehabil.* 2005;25:11-13.
43. Lichtman JH, Bigger Jr JT, Blumenthal JA, Frasure-Smith N, Kaufmann PG, Lespérance F, et al. Depression and coronary heart disease: recommendations for screening, referral, and treatment: a science advisory from the American Heart Association Prevention Committee of the Council on Cardiovascular Nursing, Council on Clinical Cardiology, Council on Epidemiology and Prevention, and Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by the American Psychiatric Association. *Circulation.* 2008;118:1768-1775.
44. Cahill M, Bilanovic A, Kelly S, Bacon S, Grace SL. Screening for depression in cardiac rehabilitation: a review. *J Cardiopulm Rehabil Prev.* 2015;35:225-230.
45. Bech P. *Clinical Psychometric.* John Wiley & Sons Ltd: Oxford, UK. 2012.
46. Mental Health Services. WHO-5 questionnaires. <http://www.psychiatri-regionh.dk/who5/menu/WHO-5+Questionnaire/>. [accessed 20 Feb 2014].
47. Rosengren A, Hawken S, Ounpuu S, Sliwa K, Zubaid M, Almahmeed WA, et al. Association of psychosocial risk factors with risk of acute myocardial infarction in 11119 cases and 13648 controls from 52 countries (the INTERHEART study): case-control study. *Lancet.* 2004;364:953-962.
48. Friedewald WT, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. *Clin Chem.* 1972;18:499-502.
49. Martin SS, Blaha MJ, Elshazly MB, Brinton EA, Toth PP, McEvoy JW, et al. Friedewald-estimated versus directly measured low-density lipoprotein cholesterol and treatment implications. *J Am Coll Cardiol.* 2013;62:732-739.
50. Mora S, Rifai N, Buring JE, Ridker PM. Comparison of LDL cholesterol concentrations by Friedewald calculation and direct measurement in relation to cardiovascular events in 27 331 women. *Clin Chem.* 2009;55:888-894.
51. Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. *JAMA.* 2007;298:309-316.
52. Campbell NRC, Berbari AE, Cloutier L, Gelfer M, Kenerson JG, Khalsa TK, et al. Policy statement of the world hypertension league on noninvasive blood pressure measurement devices and blood pressure measurement in the clinical or community setting. *J Clin Hypertens (Greenwich).* 2014;16:320-322.
53. World Health Organization. *Affordable Technology: Blood Pressure Measuring Devices for Low Resource Settings.* Geneva: WHO. 2005.
54. Gee ME, Campbell N, Sarrafzadegan N, Jafar T, Khalsa TK, Mangat B, et al. Standards for the uniform reporting of hypertension in adults using population survey data: recommendations from the world hypertension league expert committee. *J Clin Hypertens (Greenwich).* 2014;16:773-781.
55. Iqbal R, Anand S, Ounpuu S, Islam S, Zhang X, Rangarajan S, et al. Dietary patterns and the risk of acute myocardial infarction in 52 countries: results of the INTERHEART study. *Circulation.* 2008;118:1929-1937.
56. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. *Lancet.* 2004;364:937-952.
57. Krauss RM, Eckel RH, Howard B, Appel LJ, Daniels SR, Deckelbaum RJ, et al. AHA dietary guidelines: revision 2000: a statement for healthcare professionals from the Nutrition Committee of the American Heart Association. *Circulation.* 2000;102:2284-2299.
58. Popkin BM. Global nutrition dynamics: the world is shifting rapidly toward a diet linked with noncommunicable diseases. *Am J Clin Nutr.* 2006;84:289-298.
59. DiNicolantonio J, Lucan S, O'Keefe H. The evidence for saturated fat and for sugar related to coronary heart disease. *Prog Cardiovasc Dis.* 2016;58:464-472.
60. DiNicolantonio J, O'Keefe H. Hypertension due to toxic white crystals in the diet: should we blame salt or sugar? *Prog Cardiovasc Dis.* 2016;59:219-225.



61. O'Keefe E, DiNicolantonio J, Patil H, Helzberg JH3, Lavie CJ. Lifestyle choices fuel epidemics of diabetes and cardiovascular disease among Asian Indians. *Prog Cardiovasc Dis*. 2016;58:505–513.
62. Kabagambe EK, Baylin A, Campos H. Nonfatal acute myocardial infarction in Costa Rica: modifiable risk factors, population-attributable risks, and adherence to dietary guidelines. *Circulation*. 2007;115:1075–1081.
63. Teo K, Lear S, Islam S, Mony P, Dehghan M, Li W, et al. Prevalence of a healthy lifestyle among individuals with cardiovascular disease in high-, middle- and low-income countries: the Prospective Urban Rural Epidemiology (PURE) study. *JAMA*. 2013;309:1613–1621.
64. Wood DA, Kotseva K, Connolly S, Jennings C, Mead A, Jones J, et al. Nurse-coordinated multidisciplinary, family-based cardiovascular disease prevention programme (EUROACTION) for patients with coronary heart disease and asymptomatic individuals at high risk of cardiovascular disease: a paired, cluster-randomised controlled trial. *Lancet*. 2008;371:1999–2012.
65. Giannuzzi P, Temporelli PL, Marchioli R, Maggioni AP, Balestroni G, Ceci V, et al. Global secondary prevention strategies to limit event recurrence after myocardial infarction: results of the GOSPEL study, a multicenter, randomized controlled trial from the Italian cardiac rehabilitation network. *Arch Intern Med*. 2008;168:2194–2204.
66. Estruch R, Ros E, Salas-Salvadó J, Covas MI, Corella D, Arós F, et al. Primary prevention of cardiovascular disease with a Mediterranean diet. *N Engl J Med*. 2013;368:1279–1290.
67. Hu FB, Willett WC. Optimal diets for prevention of coronary heart disease. *JAMA*. 2002;288:2569–2578.
68. World Health Organization. *Interventions on Diet and Physical Activity: What Works*. Geneva: WHO. 2009.
69. Buller DB, Morrill C, Taren D, Aickin M, Sennott-Miller L, Buller MK, et al. Randomized trial testing the effect of peer education at increasing fruit and vegetable intake. *J Natl Cancer Inst*. 1999;91:1491–1500.
70. Mendis S, Puska P, Norrving B. *Global Atlas on Cardiovascular Disease Prevention and Control*. Geneva: WHO. 2011.
71. Perez-Stable E, Viswanath K, Fagan P, Vallone D, Buchting FO. Global tobacco inequalities: a new frontier. *Cancer Causes Control*. 2012;23:1–5.
72. Sarkar BK, Reddy KS. Priorities for tobacco control research in India. *Addiction*. 2012;107:2066–2068.
73. Stead LF, Bergson G, Lancaster T. Physician advice for smoking cessation. *Cochrane Database Syst Rev*. 2008;2, CD000165, <http://dx.doi.org/10.1002/14651858.CD000165.pub3>.
74. Lemmens V, Oenema A, Knut IK, Brug J. Effectiveness of smoking cessation interventions among adults: a systematic review of reviews. *Eur J Cancer Prev*. 2008;17:535–544.
75. Stead LF, Hartmann-Boyce J, Perera R, Lancaster T. Telephone counselling for smoking cessation. *Cochrane Database Syst Rev*. 2013;8, CD002850, <http://dx.doi.org/10.1002/14651858.CD002850.pub3>.
76. Rice VH, Hartmann-Boyce J, Stead LF. Nursing interventions for smoking cessation. *Cochrane Database Syst Rev*. 2013;8, CD001188, <http://dx.doi.org/10.1002/14651858.CD001188.pub4>.
77. Lancaster T, Stead LF. Self help interventions for smoking cessation. *Cochrane Database Syst Rev*. 2005;2, CD001118.
78. Stead LF, Lancaster T. Group behaviour therapy programmes for smoking cessation. *Cochrane Database Syst Rev*. 2005;2, CD001007.
79. Hartmann-Boyce J, Stead LF, Cahill K, Lancaster T. Efficacy of interventions to combat tobacco addiction: Cochrane update of 2012 reviews. *Addiction*. 2013;108:1711–1721.
80. Whittaker R, McRobbie H, Bullen C, Borland R, Rodgers A, Gu Y. Mobile phone-based interventions for smoking cessation. *Cochrane Database of Syst Rev*. 2012, CD006611, <http://dx.doi.org/10.1002/14651858.CD006611.pub3>.
81. Stead L, Perera R, Bullen C, Mant D, Hartmann-Boyce J, Cahill K, et al. Nicotine replacement therapy for smoking cessation. *Cochrane Database Syst Rev*. 2012;11, CD000146, <http://dx.doi.org/10.1002/14651858>.
82. Cahill K, Stevens S, Perera R, Lancaster T. Pharmacological interventions for smoking cessation: an overview and network meta-analysis. *Cochrane Database Syst Rev*. 2013;5, CD009329.
83. Hajek P, McRobbie H, Myers K. Efficacy of cytisine in helping smokers quit: systematic review and meta-analysis. *Thorax*. 2013;68:1037–1042.
84. Stead L, Lancaster T. Combined pharmacotherapy and behavioural interventions for smoking cessation (review). *Cochrane Database Syst Rev*. 2012;10, CD008286, <http://dx.doi.org/10.1002/14651858.CD008286.pub2>.
85. World Health Organization. *WHO CVD-Risk Management Package for Low- and Medium-Resource Settings*. Geneva: WHO. 2002.
86. McEwen A, Hajek P, McRobbie H, West R. *The Manual of Smoking Cessation: a Guide for Counsellors and Practitioners*. Oxford, UK: Blackwell Publishing Ltd. 2006.
87. Ahluwalia JS, Harris K, Catley D, Okuyemi KS, Mayo MS. Sustained-release bupropion for smoking cessation in African Americans: a randomized controlled trial. *JAMA*. 2002;288:468–474.
88. Kumar R, Kushwaha AS, Mahakud GC, Okuyemi KS, Mayo MS, et al. Smoking cessation interventions and continuous abstinence rate at one year. *Indian J Chest Dis Allied Sci*. 2007;49:201–207.
89. Jain R, Jhanjee S, Jain V, Gupta T, Mittal S, Goelz P, et al. A double-blind placebo-controlled randomized trial of varenicline for smokeless tobacco dependence in India. *Nicotine Tob Res*. 2014;16:50–57.
90. West R, Zatonski W, Cedzynska M, Lewandowska D, Pazik J, Aveyard P, et al. Placebo-controlled trial of cytisine for smoking cessation. *N Engl J Med*. 2011;365:1193–1200.
91. West R, McNeill A, Raw M. Verifiable CPD paper: smokeless tobacco cessation guidelines for health professionals in England. *Br Dent J*. 2004;196:611–618.
92. Ebbert J, Montori VM, Erwin PJ, Stead LF. Interventions for smokeless tobacco use cessation. *Cochrane Database Syst Rev*. 2011;2, CD004306, <http://dx.doi.org/10.1002/14651858.CD004306.pub4>.
93. Lavie CJ, De Schutter A, Parto P, Jahangir E, Kokkinos P, Ortega FB, et al. Obesity and prevalence of cardiovascular diseases and prognosis—the obesity paradox updated. *Prog Cardiovasc Dis*. 2016;58:537–547.
94. Cooney M, Reiner Z, Sheu W, Ryden L, Sutter Jd, De Bacquer D, et al. SURF—survey of risk factor management: first report of an international audit. *Eur J Prev Cardiol*. 2014;21:813–822.
95. Liu L, Ma J, Yin X, Kelepouris E, Eisen HJ. Global variability in angina pectoris and its association with body mass index and poverty. *Am J Cardiol*. 2011;107:655–661.
96. Chen Y, Copeland WK, Vedanthan R, Grant E, Lee JE, Gu D, et al. Association between body mass index and cardiovascular disease mortality in East Asians and South Asians: pooled analysis of prospective data from the Asia cohort consortium. *BMJ*. 2013;347:f5446, <http://dx.doi.org/10.1136/bmj.f5446>.
97. Lanús F, Avezum A, Bautista LE, Diaz R, Luna M, Islam S, et al. Risk factors for acute myocardial infarction in Latin America: the INTERHEART Latin American study. *Circulation*. 2007;115:1067–1074.
98. World Health Organization. *Global Action Plan for the Prevention and Control of Noncommunicable Diseases 2013–2020*. Geneva: WHO. 2013.

99. Jensen MD, Ryan DH, Apovian CM, Ard JD, Comuzzie AG, Donato KA, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Obesity Society. *J Am Coll Cardiol*. 2014;63:2985-3023.
100. Michaud PC, Goldman DP, Lakdawalla DN, Zheng Y, Gailey AH. The value of medical and pharmaceutical interventions for reducing obesity. *J Health Econ*. 2012;31:630-643.
101. Pogosova N, Saner H, Pedersen SS, Cupples ME, McGee H, Höfer S, et al. Psychosocial aspects in cardiac rehabilitation: from theory to practice a position paper from the cardiac rehabilitation section of the European Association of Cardiovascular Prevention and Rehabilitation of the European Society of Cardiology. *Eur J Prev Cardiol*. 2015;22:1290-1306.
102. Lichtman JH, Froelicher ES, Blumenthal JA, Carney RM, Doering LV, Frasure-Smith N, et al. Depression as a risk factor for poor prognosis among patients with acute coronary syndrome: systematic review and recommendations: a scientific statement from the American Heart Association. *Circulation*. 2014. <http://dx.doi.org/10.1161/CIR.0000000000000019>.
103. American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders*. 5 ed. Arlington, VA: American Psychiatric Publishing. 2013.
104. Thombs BD, Roseman M, Coyne JC, de Jonge P, Delisle VC, Arthurs E, et al. Does evidence support the American Heart Association's recommendation to screen patients for depression in cardiovascular care? An updated systematic review. *PLoS One*. 2013;8:e52654. <http://dx.doi.org/10.1371/journal.pone.0052654>.
105. Horton R. GBD 2010: understanding disease, injury, and risk. *Lancet*. 2012;380:2053-2054.
106. Barefoot JC, Helms MJ, Mark DB, Blumenthal JA, Califf RM, Haney TL, et al. Depression and long-term mortality risk in patients with coronary artery disease. *Am J Cardiol*. 1996;78:613-617.
107. McGrady A, McGinnis R, Badenhop D, Bentle M, Rajput M. Effects of depression and anxiety on adherence to cardiac rehabilitation. *J Cardiopulm Rehabil Prev*. 2009;29:358-364.
108. Glassman AH, O'Connor CM, Califf RM, Swedberg K, Schwartz P, Bigger Jr JT, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. *JAMA*. 2002;288:701-709.
109. Enrichd WCft, Investigators. Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the Enhancing Recovery in Coronary Heart Disease Patients (ENRICH) randomized trial. *JAMA*. 2003;289:3106-3116.
110. Rutledge T, Redwine LS, Linke SE, Mills PJ. A meta-analysis of mental health treatments and cardiac rehabilitation for improving clinical outcomes and depression among patients with coronary heart disease. *Psychosom Med*. 2013;75:335-349.
111. Critchley J, Liu J, Zhao D, Wei W, Capewell S. Explaining the increase in coronary heart disease mortality in Beijing between 1984 and 1999. *Circulation*. 2004;110:1236-1244.
112. Rastam S, AL Ali R, Maziak W, Mzayek F, Fouad FM, O'Flaherty M, et al. Explaining the increase in coronary heart disease mortality in Syria between 1996 and 2006. *BMC Public Health*. 2012;12:754. <http://dx.doi.org/10.1186/1471-2458-12-754>.
113. Cholesterol Treatment Trialists Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. *Lancet*. 2010;376:1670-1681.
114. Lopez-Jimenez F, Simha V, Thomas RJ, Allison TG, Basu A, Fernandes R, et al. A summary and critical assessment of the 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: filling the gaps. *Mayo Clin Proc*. 2014;89:1257-1278.
115. Expert Panel. *Third Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)*. NHLBI: Bethesda, MD. 2002.
116. Chen Z, Chen J, Collins R, Guo Y, Peto R, Wu F, et al. China Kadoorie Biobank of 0.5 million people: survey methods, baseline characteristics and long-term follow-up. *Int J Epidemiol*. 2011;40:1652-1666.
117. Nieuwlaat R, Wilczynski N, Navarro T, Hobson N, Jeffery R, Keenanasseril A, et al. Interventions for enhancing medication adherence. *Cochrane Database of Syst Rev*. 2014;11, CD000011. <http://dx.doi.org/10.1002/14651858.CD000011.pub4>.
118. Sanz G, Fuster V. Polypill and global cardiovascular health strategies. *Semin Thorac Cardiovasc Surg*. 2011;23:24-29.
119. Lim L, Haq N, Mahmood S, Hoeksema L. ACPM Prevention Practice Committee, American College of Preventive Medicine. Atherosclerotic cardiovascular disease screening in adults: American College of Preventive Medicine position statement on preventive practice. *Am J Prev Med*. 2011;40:e1-e10.
120. World Health Organization. *A Global Brief on Hypertension: Silent Killer, Global Public Health Crisis World Health Day 2013*. Geneva: WHO. 2013.
121. Dasgupta K, Quinn RR, Zarnke KB, Rabi DM, Ravani P, Daskalopoulou SS, et al. The 2014 Canadian hypertension education program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. *Can J Cardiol*. 2014;30:485-501.
122. Lopez-Jimenez F, Kramer VC, Masters B, Stuart PM, Mullooly C, Hinshaw L, et al. Recommendations for managing patients with diabetes mellitus in cardiopulmonary rehabilitation: an American association of cardiovascular and pulmonary rehabilitation statement. *J Cardiopulm Rehabil Prev*. 2012;32:101-112.
123. Ghisi GL, Abdallah F, Grace SL, Thomas S, Oh P. A systematic review of patient education in cardiac patients: do they increase knowledge and promote health behavior change? *Patient Educ Couns*. 2014;95:160-174.
124. Aldcroft SA, Taylor NF, Blackstock FC, O'Halloran PD. Psychoeducational rehabilitation for health behavior change in coronary artery disease: a systematic review of controlled trials. *J Cardiopulm Rehabil Prev*. 2011;31:273-281.
125. Brown JPR, Clark AM, Dalal H, Welch K, Taylor RS. Effect of patient education in the management of coronary heart disease: a systematic review and meta-analysis of randomized controlled trials. *Eur J Prev Cardiol*. 2013;20:701-714.
126. Irmak Z, Fesci H. Effects of nurse-managed secondary prevention program on lifestyle and risk factors of patients who had experienced myocardial infarction. *Appl Nurs Res*. 2010;23:147-152.
127. Doak CC, Doak LG, Root JH. *Teaching Patients with Low Literacy Skills*. ed. 2. Philadelphia, Pennsylvania: JB Lippincott. 2007.
128. Schwarzer R. Self-Efficacy in the Adoption and Maintenance of Health Behaviors: Theoretical Approaches and a New Model. In: Schwarzer R, ed. *Self-Efficacy: Thought Control of Action*. Washington, DC: Hemisphere; 1992. p. 217-242.
129. Bandura A. *Social Foundations of Thought and Action: a Social Cognitive Theory*. New Jersey, Prentice-Hall: Englewood Cliffs. 1986.
130. Knowles MS. *The Modern Practice of Adult Education*. New York: Association Press. 1980.
131. Haskell WL, Alderman EL, Fair JM, Maron DJ, Mackey SF, Superko HR, et al. Effects of intensive multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women with coronary artery disease. The Stanford Coronary Risk Intervention Project (SCRIP). *Circulation*. 1994;89:975-990.
132. DeBusk RF, Miller NH, Superko HR, Dennis CA, Thomas RJ, Lew HT, et al. A case-management system for coronary risk factor modification after acute myocardial infarction. *Ann Intern Med*. 1994;120:721-729.

133. Berra K, Miller NH, Jennings C. Nurse-based models for cardiovascular disease prevention: from research to clinical practice. *J Cardiovasc Nurs.* 2011;26:S46-S55.
134. Koovor P, Lee AKY, Carrozzi F, Wiseman V, Byth K, Zecchin R, et al. Return to full normal activities including work at two weeks after acute myocardial infarction. *Am J Cardiol.* 2006;97:952-958.
135. Hall R, Joseph D, Schwartz-Barcott D. Behavioral maintenance: a closer look. *Nurs Forum.* 2002;37:5-11.
136. American College of Sports Medicine, Balady G. *ACSM's Guidelines for Exercise Testing and Prescription.* ed. 6. Philadelphia, Pennsylvania: Lippincott Williams and Wilkins. 2000.
137. Isaz K, Coudrot M, Sabry MH, Cerisier A, Lamaud M, Robin C, et al. Return to work after acute ST-segment elevation myocardial infarction in the modern era of reperfusion by direct percutaneous coronary intervention. *Arch Cardiovasc Dis.* 2010;103:310-316.
138. Buckley JP, Furze G, Doherty P, Speck L, Connolly S, Hinton S, et al. BACPR scientific statement: British standards and core components for cardiovascular disease prevention and rehabilitation. *Heart.* 2013;99:1069-1071.
139. Myers J, Prakash M, Froelicher V, Do D, Partington S, Atwood JE. Exercise capacity and mortality among men referred for exercise testing. *NEJM.* 2002;346:793-801.
140. Bravata DM, Smith-Spangler C, Sundaram V, Gienger AL, Lin N, Lewis R, et al. Using pedometers to increase physical activity and improve health: a systematic review. *JAMA.* 2007;298:2296-2304.
141. Ghisi GL, Durieux A, Manfroi WC, Herdy AH, Carvalho Td, Andrade A, et al. Construction and validation of the CADE-Q for patient education in cardiac rehabilitation programs. *Arq Bras Cardiol.* 2010;94:813-822.
142. Ghisi GL, Grace SL, Thomas S, Evans MF, Oh P. Development and psychometric validation of the second version of the coronary artery disease education questionnaire (CADE-Q II). *Patient Educ Couns.* 2015;98:378-383.
143. Bech P. Measuring the dimension of psychological general well-being by the WHO-5. *Qual Life Newsl.* 2004;32:15-16.
144. Rosendorff C, Lackland DT, Allison M, Aronow WS, Black HR, Blumenthal RS, et al. Treatment of hypertension in patients with coronary artery disease: a scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. *J Am Coll Cardiol.* 2015;65:1998-2038.
145. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. *Med Care.* 1986;24:67-74.
146. Grace SL, Poirier P, Norris CM, Oakes GH, Somanader DS, Suskin N, et al. Pan-Canadian development of cardiac rehabilitation and secondary prevention quality indicators. *Can J Cardiol.* 2014;30:945-948.
147. Grace SL, Bennetta S, Ardern C, Clark AM. Cardiac rehabilitation series: Canada. *Prog Cardiovasc Dis.* 2014;56:530-535.
148. Redfern J, Maiorana A, Neubeck L, Clark AM, Briffa T. Achieving coordinated secondary prevention of coronary heart disease for all in need (SPAN). *Int J Cardiol.* 2011;146:1-3.
149. Sjöström-Strand A, Ivarsson B, Sjöberg T. Primary health care resources for rehabilitation and secondary prevention after myocardial infarction — a questionnaire survey. *Scand J Caring Sci.* 2013;27:260-266.
150. Dalal HM, Zawada A, Jolly K, Moxham T, Taylor RS. Home based versus centre based cardiac rehabilitation: Cochrane systematic review and meta-analysis. *BMJ.* 2010;340, <http://dx.doi.org/10.1136/bmj.b5631>.
151. Humphrey R, Guazzi M, Niebauer J. Cardiac rehabilitation in Europe. *Prog Cardiovasc Dis.* 2014;56:551-556.
152. Clark RA, Conway A, Poulsen V, Keech W, Tirimacco R, Tideman P. Alternative models of cardiac rehabilitation: a systematic review. *Eur J Prev Cardiol.* 2015;22:35-74.
153. Mosleh SM, Bond CM, Lee AJ, Kiger A, Campbell NC. Effects of community based cardiac rehabilitation: comparison with a hospital-based programme. *Eur J Cardiovasc Nurs.* 2015;14:108-116.
154. Centre for Disease Control Research and Development NHRD Ministry of Health Republic of Indonesia in Collaboration with World Health Organization: *Monitoring and Evaluation of the Integrated Community-Based Intervention for the Prevention of Noncommunicable Diseases in Depok, West Java, Indonesia.* Jakarta: MOH. 2006.
155. Radi B. S36-3 cardiac rehabilitation in Indonesia. *Glob Heart.* 2009;4:S49.
156. Madan K, Babu AS, Contractor A, Sawhney JP, Prabhakaran D, Gupta R. Cardiac rehabilitation in India. *Prog Cardiovasc Dis.* 2014;56:543-550.
157. Singapore Heart Foundation. The SHF heart wellness Centre. <http://www.myheart.org.sg/article/cardiac-rehabilitation-and-heart-wellness/shf-isetan-foundation-heart-wellness-centre/about-us/27>. [accessed 12 May 2014].
158. Tay H, Kwan Y, Ong K, Chang JY. Heart wellness programme—a community based cardiac rehabilitation and primary prevention programme to reduce cardiovascular disease in a multi-ethnic society. *Ann Acad Med.* 2013;42(Suppl 9).
159. Rajendran A, Manoj S, Karthikeyan D, Davis S. Cardiac rehabilitation for CABG patients in south Indian setup : a prospective study. *IJPMR.* 2004;15:23-33.
160. Poortaghi S, Baghernia A, Golzari SEJ, Safayian A, Atri SB. The effect of home-based cardiac rehabilitation program on self efficacy of patients referred to cardiac rehabilitation center. *BMC Res Notes.* 2013;6:287, <http://dx.doi.org/10.1186/1756-0500-6-287>.
161. Salvetti XM, Oliveira JA, Servantes DM, Vincenzo de Paola AA. How much do the benefits cost? Effects of a home-based training programme on cardiovascular fitness, quality of life, programme cost and adherence for patients with coronary disease. *Clin Rehabil.* 2008;22:987-996.
162. Wang W, Chair SY, Thompson DR, Twinn SF. Effects of home-based rehabilitation on health-related quality of life and psychological status in Chinese patients recovering from acute myocardial infarction. *Heart Lung.* 2012;41:15-25.
163. Beatty AL, Fukuoka Y, Whooley MA. Using mobile technology for cardiac rehabilitation: a review and framework for development and evaluation. *J Am Heart Assoc.* 2013;2:e000568, <http://dx.doi.org/10.1161/JAHA.113.000568>.
164. Varnfield M, Karunanithi M, Lee CK, Honeyman E, Arnold D, Ding H, et al. Smartphone-based home care model improved use of cardiac rehabilitation in postmyocardial infarction patients: results from a randomised controlled trial. *Heart.* 2014;100:1770-1779.
165. Alsaleh E, Blake H, Windle R. Behavioural intervention to increase physical activity among patients with coronary heart disease: protocol for a randomised controlled trial. *Int J Nurs Stud.* 2012;49:1489-1493.
166. Källander K, Tibenderana JK, Akpogheneta OJ, Strachan DL, Hill Z, ten Asbroek AH, et al. Mobile health (mHealth) approaches and lessons for increased performance and retention of community health workers in low- and middle-income countries: a review. *J Med Internet Res.* 2013;15:e17, <http://dx.doi.org/10.2196/jmir.2130>.
167. ITU. ITU: Statshot. <http://www.itu.int/en/ITU-D/Statistics/Pages/stat/default.aspx> 2014. [accessed 12 May 2014].
168. Pop-Eleches C, Thirumurthy H, Habyarimana JP, Zivin JG, Goldstein MP, de Walque D, et al. Mobile phone technologies improve adherence to antiretroviral treatment in a

- resource-limited setting: a randomized controlled trial of text message reminders. *AIDS*. 2011;25:825-834.
169. Maddison R, Pfaeffli L, Whittaker R, Stewart R, Kerr A, Jiang Y, et al. A mobile phone intervention increases physical activity in people with cardiovascular disease: results from the HEART randomized controlled trial. *Eur J Prev Cardiol*. 2015;22:701-709.
170. Esterson YB, Carey M, Piette JD, Thomas N, Hawkins M. A systematic review of innovative diabetes care models in low-and middle-income countries (LMICs). *J Health Care Poor Underserved*. 2014;25:72-93.
171. World Health Organization. *Prevention and Control of Noncommunicable Diseases: Guidelines for Primary Health Care in Low Resource Settings*. Geneva: WHO. 2012.